<?xml version="1.0" encoding="UTF-8"?><doc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" zoom="100"><mdata projectname="OUP" category="NAR"><mta name="article-type">research-article</mta><mta name="publisher-id">gkaf2001</mta><mta name="category-oup-series">NA</mta><mta name="category-subject-doi">NA</mta><mta name="category-taxonomy-collection">AcademicSubjects/SCI00010</mta><mta name="category-taxonomy-collection1">NA</mta><mta name="doi">10.1093/nar/gkaf2001</mta><mta name="supplementary-material-label" id="featfig">Graphical Abstract Figure.</mta><mta name="supplementary-material-caption">bbbbbbbbb</mta><mta name="supplementary-material-graphic" label="image">gkaf2001_gra.jpg</mta><mta name="pub-date-ppub">00-00-2025</mta><mta name="pub-date-epub">00-00-2025</mta><mta name="pub-date-collection">00-00-2025</mta><mta name="cover-date">00-2025</mta><mta name="volume">0</mta><mta name="issue">0</mta><mta name="fpage">1</mta><mta name="lpage">0</mta><mta name="elocation-id">00</mta><mta name="copyright-statement">© The Author(s) 2025. Published by Oxford University Press on behalf of Nucleic Acids Research.<?break ?>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</mta><mta name="copyright-year">2025</mta><mta name="corrected-typeset">DD-MM-YYYY</mta><mta name="meta-name" exinfo="M1">edited-state</mta><mta name="meta-value">corrected-proof</mta><mta name="meta-name" exinfo="M2">article-lifecycle</mta><mta name="meta-value">PAP</mta><mta name="self-uri" exinfo="">gkaf2001.pdf</mta><mta name="feature-fig-label-1">NA</mta><mta name="feature-fig-image-1" exinfo="IMG">NA</mta><mta name="feature-fig-label-2">NA</mta><mta name="feature-fig-image-2" exinfo="IMG">NA</mta><mta name="feature-fig-label-3">NA</mta><mta name="feature-fig-image-3" exinfo="IMG">NA</mta><mta name="source-wc">500</mta><mta name="non-printing-chars">false</mta><mta name="display-buttons">true</mta></mdata><fm><lrh title="Left Running Head">Wang<query><button type="button" title="AU: CE: Please provide the short title for running head." contenteditable="false" query-type="open" roleid="12" conversation-uid="3" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">3</span></button></query><i>et al.</i></lrh><rrh title="Right Running Head">Homeodomain protein PRRX1 anchors the Ku heterodimers at DNA</rrh><dochead title="Doc Head">Genome Integrity, Repair and Replication</dochead><ti title="Document Title">Test1111-Homeodomain protein PRRX1 anchors the Ku heterodimers at DNA double-strand breaks to promote non-homologous end-joining<query><button type="button" title="AU: If your manuscript has figures or text from other sources, please ensure you have permission from the copyright holder. Also ensure that the copyright owner is properly credited, for instance in the figure legends. Make any changes directly in the text. For any questions about permissions, contact jnls.author.support@oup.com." contenteditable="false" query-type="open" roleid="12" conversation-uid="1" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">1</span></button></query><query><button type="button" title="AU: CE: It is mandatory to insert a query for the author if any grammatical and stylistic changes are made in the title of the paper. Please insert an author query for the changes made in the title." contenteditable="false" query-type="open" roleid="12" conversation-uid="2" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">2</span></button></query>
</ti><aug title="Authors" sep=", " lsep=""><au suffix="1,2,#" rid="aff1 aff2 afn1"><f title="First name">Yan</f><s title="Surname">Wang</s></au><au suffix="1,2,#" rid="aff1 aff2 afn1"><f title="First name">Fuyuan</f><s title="Surname">Shen</s></au><au suffix="1,2" rid="aff1 aff2"><f title="First name">Chen</f><s title="Surname">Zhao</s></au><au suffix="1,2" rid="aff1 aff2"><f title="First name">Jiali</f><s title="Surname">Li</s></au><au suffix="1,2" rid="aff1 aff2"><f title="First name">Wen</f><s title="Surname">Wang</s></au><au suffix="3" rid="aff3"><f title="First name">Yamu</f><s title="Surname">Li</s></au><au suffix="1,2" rid="aff1 aff2"><f title="First name">Jia</f><s title="Surname">Gan</s></au><au suffix="2" rid="aff2"><f title="First name">Haojian</f><s title="Surname">Zhang</s></au><au suffix="2" rid="aff2"><f title="First name">Xuefeng</f><s title="Surname">Chen</s></au><au suffix="2" rid="aff2"><f title="First name">Qiang</f><s title="Surname">Chen</s></au><au suffix="1,2,*" rid="aff1 aff2 cor1"><f title="First name">Fangyu</f><s title="Surname">Wang</s></au><au suffix="1,2,*" rid="aff1 aff2 cor1"><f title="First name">Ying</f><s title="Surname">Liu</s></au><au suffix="1,2,*" rid="aff1 aff2 cor1"><f title="First name">Yan</f><s title="Surname">Zhou</s></au></aug><affg type="arabic"><aff id="aff1" sno="1" type="arabic"><org title="Organization">Department of Neurosurgery, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University</org>, <str title="Street">Wuhan</str>, <cny title="Country">China</cny><query><button type="button" title="AU: Please provide postal code for affiliation 1 directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="4" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">4</span></button></query><query><button type="button" title="AU: Please check the spelling and accuracy of all author names and affiliations, particularly for any co-authors. Also check that author surnames are correctly highlighted. This is to ensure that forenames and surnames are tagged correctly for online indexing. Incorrect names and affiliations may lead to an author not being credited for their work by funders, institutions, or other third parties. Make any changes directly in the text. Note that changes to your authorship list (adding or removing authors, changing designation of corresponding author) require additional approvals. Email jnls.author.support@oup.com if this is required." contenteditable="false" query-type="open" roleid="12" conversation-uid="5" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">5</span></button></query></aff><aff id="aff2" sno="2" type="arabic"><org title="Organization">Frontier Science Center of Immunology and Metabolism, Wuhan University</org>, <str title="Street">Wuhan</str>, <cny title="Country">China</cny><query><button type="button" title="AU: Please provide postal code for affiliation 2 directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="6" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">6</span></button></query></aff><aff id="aff3" sno="3" type="arabic"><org title="Organization">The First Affiliated Hospital of Henan University</org><query><button type="button" title="AU: Please provide postal code/city/country for affiliation 3 directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="7" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">7</span></button></query></aff></affg><coraddg type="symbol"><coradd title="Cor Address" id="cor1" sno="*" type="symbol">To whom correspondence should be addressed. Emails: <email href="mailto:fangyu.wang@whu.edu.cn" title="e-Mail">fangyu.wang@whu.edu.cn</email>; <email href="mailto:y.liu@whu.edu.cn" title="e-Mail">y.liu@whu.edu.cn</email>; <email href="mailto:yan.zhou@whu.edu.cn" title="e-Mail">yan.zhou@whu.edu.cn</email><query><button type="button" title="AU: CE: phone is missing, please provide." contenteditable="false" query-type="open" roleid="12" conversation-uid="8" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">8</span></button></query><query><button type="button" title="AU: CE: Fax is missing, please provide." contenteditable="false" query-type="open" roleid="12" conversation-uid="9" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">9</span></button></query></coradd></coraddg><noteg type="symbol"><note type="symbol" id="afn1" sno="#">Equal contribution</note></noteg><hsy title="History" sep=";" id="d3e304"><re>October 25, 2024</re><rsd>January 26, 2025</rsd><edd>February 26, 2025</edd><acd>March 3, 2025</acd></hsy><absg><ti title="Abstract Head">Abstract</ti><p t="fl" title="Paragraph No Indent">The DNA-PK complex plays a critical role in non-homologous end-joining (NHEJ), a template-independent pathway for repairing DNA double-strand breaks (DSBs). The association of Ku70/80 with DSB ends facilitates the assembly of the DNA-PK holoenzyme. However, key mechanisms underlying the attachment and stabilization of DNA-PK at broken DNA ends remain unclear. Here, we identify PRRX1, a homeodomain-containing protein, as a mediator of chromatin localization and subsequent activation of DNA-PK. PRRX1 oligomerizes to simultaneously bind to double-strand DNA and the SAP domain of Ku70, thereby enhancing Ku anchoring at DSBs and stabilizing DNA-PK for efficient NHEJ repair. Reduced expression or pathogenic mutations of PRRX1 are associated with genomic instability and impaired NHEJ repair. Furthermore, a peptide that disrupts PRRX1 oligomerization compromises NHEJ efficiency and reduces cell survival following irradiation. These findings provide new insights into the activation of the NHEJ machinery and offer potential strategies for optimizing cancer therapies<query><button type="button" title="AU: The abstract has been edited as a single paragraph to match journal style. Please edit, if necessary, directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="10" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">10</span></button></query>.<query><button type="button" title="AU: Please provide a short caption for the graphical abstract." contenteditable="false" query-type="open" roleid="12" conversation-uid="11" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">11</span></button></query></p></absg><absg exinfo="graphical"><ti title="Abstract Head">Graphical Abstract</ti><fig id="fig1g"><ti title="Abstract Head">aaaaaaaaaaaa</ti><img src="gkaf2001_gra.jpg" title="Figure"></img></fig>
</absg></fm><bdy><sect1 id="sec1" sec-type="intro"><ti title="Heading 1">Introduction</ti><p t="fl" title="Paragraph No Indent">DNA double-strand breaks (DSBs) are among the most deleterious genomic lesions in mammalian cells [<bibcit rid="bib1" title="bibcit" href="#" contenteditable="false" id="link_d3e37328" sno="1">1</bibcit>, <bibcit rid="bib2" title="bibcit" href="#" contenteditable="false" id="link_d3e37629" sno="2">2</bibcit>, <bibcit rid="bib3" title="bibcit" href="#" contenteditable="false" id="link_d3e37930" sno="3">3</bibcit>]. DSBs are primarily repaired through two classical pathways [<bibcit rid="bib4" title="bibcit" href="#" contenteditable="false" id="link_d3e38231" sno="4">4</bibcit>, <bibcit rid="bib5" title="bibcit" href="#" contenteditable="false" id="link_d3e38532" sno="5">5</bibcit>, <bibcit rid="bib6" title="bibcit" href="#" contenteditable="false" id="link_d3e38933" sno="6">6</bibcit>]: non-homologous end-joining (NHEJ) and homologous recombination (HR). HR utilizes homologous DNA sequences as a template, making it a high-fidelity repair mechanism favored during the S/G2 phase of the cell cycle [<bibcit rid="bib7" title="bibcit" href="#" contenteditable="false" id="link_d3e39234" sno="7">7</bibcit>,<bibcit rid="bib8" title="bibcit" href="#" contenteditable="false" id="link_d3e39535" sno="8">8</bibcit>]. In contrast, NHEJ is a rapid but error-prone DNA repair process that directly rejoins broken DNA strands without requiring a template and remains active throughout the cell cycle [<bibcit rid="bib9" title="bibcit" href="#" contenteditable="false" id="link_d3e39836" sno="9">9</bibcit>,<bibcit rid="bib10" title="bibcit" href="#" contenteditable="false" id="link_d3e40137" sno="10">10</bibcit>]. Overactivation of DNA damage repair (DDR) mechanisms, including NHEJ, is commonly observed in cancer cells, contributing to resistance against radiotherapy and chemotherapy. This presents a significant challenge in cancer treatment that demands urgent attention [<bibcit rid="bib11" title="bibcit" href="#" contenteditable="false" id="link_d3e40438" sno="11">11</bibcit>,<bibcit rid="bib12" title="bibcit" href="#" contenteditable="false" id="link_d3e40839" sno="12">12</bibcit>].</p><p t="i" title="Paragraph Indented">In NHEJ, DSB ends are initially recognized and bound by the Ku70/80 heterodimer, which, acting as a scaffold, recruits the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) to form the DNA-PK complex. Subsequently, DNA-PK is activated by DNA ends to initiate the repair [<bibcit rid="bib13" title="bibcit" href="#" contenteditable="false" id="link_d3e41340" sno="13">13</bibcit>,<bibcit rid="bib14" title="bibcit" href="#" contenteditable="false" id="link_d3e41641" sno="14">14</bibcit>]. The crystal structure of the Ku heterodimer reveals that each Ku70/80 subunit consists of three distinct regions: the N-terminal vWA (von Willebrand A) domain, a β-barrel domain associated with dimerization, and the C-terminal domain [<bibcit rid="bib15" title="bibcit" href="#" contenteditable="false" id="link_d3e41942" sno="15">15</bibcit>,<bibcit rid="bib16" title="bibcit" href="#" contenteditable="false" id="link_d3e42243" sno="16">16</bibcit>]. The C-terminal extension of Ku80 contributes to the stabilization of the DNA-PK complex [<bibcit rid="bib17" title="bibcit" href="#" contenteditable="false" id="link_d3e42544" sno="17">17</bibcit>,<bibcit rid="bib18" title="bibcit" href="#" contenteditable="false" id="link_d3e42945" sno="18">18</bibcit>], while the SAP (SAF-A/B, Acinus and PIAS) domain of Ku70 C-terminal is essential for the stable association of the Ku70/80 heterodimer with double-stranded DNA (dsDNA) ends <i>in vitro</i> [<bibcit rid="bib19" title="bibcit" href="#" contenteditable="false" id="link_d3e43546" sno="19">19</bibcit>, <bibcit rid="bib20" title="bibcit" href="#" contenteditable="false" id="link_d3e43847" sno="20">20</bibcit>, <bibcit rid="bib21" title="bibcit" href="#" contenteditable="false" id="link_d3e44148" sno="21">21</bibcit>]. The Ku70/80 heterodimer exhibits high affinity with broken DNA ends, independent of the DNA sequences, enabling its prompt translocation onto DSB sites. Additionally, Ku70/80 can bind directly or indirectly to various histone modifications, facilitating its recruitment to DSB-associated chromatin [<bibcit rid="bib22" title="bibcit" href="#" contenteditable="false" id="link_d3e44449" sno="22">22</bibcit>,<bibcit rid="bib23" title="bibcit" href="#" contenteditable="false" id="link_d3e44850" sno="23">23</bibcit>]. Furthermore, nuclear factors such as MRI/CYREN [<bibcit rid="bib24" title="bibcit" href="#" contenteditable="false" id="link_d3e45151" sno="24">24</bibcit>,<bibcit rid="bib25" title="bibcit" href="#" contenteditable="false" id="link_d3e45452" sno="25">25</bibcit>], LRF [<bibcit rid="bib26" title="bibcit" href="#" contenteditable="false" id="link_d3e45753" sno="26">26</bibcit>], BRN2 [<bibcit rid="bib27" title="bibcit" href="#" contenteditable="false" id="link_d3e46054" sno="27">27</bibcit>], ZNF384 [<bibcit rid="bib28" title="bibcit" href="#" contenteditable="false" id="link_d3e46355" sno="28">28</bibcit>] and SMYD2 [<bibcit rid="bib29" title="bibcit" href="#" contenteditable="false" id="link_d3e46756" sno="29">29</bibcit>], have been implicated in regulating Ku dynamics during NHEJ repair. These findings underscore the complexicity of Ku dynamics. However, critical question remain regarding how the attachment and stabilization of Ku-DNA-PKcs complex are precisely regulated on the chromatin context. Unraveling these mechanisms is essential for a comprehensive understanding of how sensor proteins respond to DSBs and initiate NHEJ.</p><p t="i" title="Paragraph Indented">PRRX1, a member of the PRD class of homeodomain (HD) protein family, plays numerous roles in regulating skeletal cartilage development, epithelial-mesenchymal transition (EMT), fibrosis, and other mesoblast lineage-related biological processes [<bibcit rid="bib30 bib31 bib32" title="bibcit" href="#" contenteditable="false" id="link_d3e47257" sno="30 31 32">30–32</bibcit>, <bibcit rid="bib33" title="bibcit" href="#" contenteditable="false" id="link_d3e47558" sno="33">33</bibcit>]. Its primary function is mediated through DNA-binding activity, either as a transcription factor or co-activator. A recent study has showed that PRRX1, in conjunction with FOXM1, promotes the expression of HR-associated genes in prostate cells [<bibcit rid="bib34" title="bibcit" href="#" contenteditable="false" id="link_d3e47859" sno="34">34</bibcit>]. In this study, we unexpectedly revealed a transcription-independent role of PRRX1 in promoting NHEJ. We found that oligomerized PRRX1 directly associates with both Ku and dsDNA to facilitate the assembly and activation of DNA-PK at DSBs. Moreover, pathogenic mutations and low expression of PRRX1 in stomach adenocarcinomas are linked to genomic instability and defective NHEJ. Notably, we demonstrated that the peptide disrupting PRRX1 oligomerization impairs NHEJ efficiency and reduces cell survival following irradiation. This study not only provides novel insight into the role of HD protein in regulating NHEJ, but also holds implications for the development of cancer treatment strategies.</p></sect1><sect1 id="sec2" sec-type="materials|methods"><ti title="Heading 1">Materials and methods</ti><sect2 id="sec2-1"><ti title="Heading 2">Animals and genotyping</ti><p t="fl" title="Paragraph No Indent">All animal procedures were approved by the Animal Care and Ethical Committee of Medical Research Institute at Wuhan University. <i>Prrx1</i><sup>+/−</sup> C57BL/6JGpt mice (Strain NO.T013725; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> IMSR_GPT:T013725) were generated by the GemPharmatech (Nanjing, China) using the CRISPR/Cas9-mediated gene editing. Two sgRNAs were designed to generate a chromosomal deletion at the second exon region of <i>Prrx1</i> in the mouse genome. Targeting vector, Cas9 vector and sgRNAs were microinjected into mouse zygotes. Zygotes were transferred into pseudo-pregnant female mice to generate founders, which were genotyped by PCR and sequencing. Positive founders were crossed with C57BL/6 wild-type mice to generate F1 mice. The primer set for genotyping is provided in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S3</url>. Band sizes for the wild-type allele and knockout (KO) allele are 614 bp and 542 bp, respectively.</p></sect2><sect2 id="sec2-2"><ti title="Heading 2">Cell cultures</ti><p t="fl" title="Paragraph No Indent">HEK293T (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_0063) cell line was a gift from Dr. Hongbing Shu (Wuhan University). MOVAS (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_0F08) cell line was a gift from Dr. Xiang Cheng (Union Hospital, Huazhong University of Science and Technology). Wild-type (CHO-AA8, <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_4386) and <i>Xrrc6</i><sup>−/−</sup> (CHO-xrs-6, <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_4340) cell lines were gifts from Dr. Dongyi Xu (Peking University). EJ5 U2OS cell line was a gift from Dr. Jun Huang (Zhejiang University). U2OS (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_0042) and Hs746.T (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_0333) cell lines were purchased from CCTCC. MEFs were generated from wild-type or E14.5 <i>Prrx1</i><sup>−</sup><i><sup>/</sup></i><sup>−</sup> C57BL/6 littermates. <i>Trp53bp1</i><sup>−/−</sup> MEF (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> CVCL_UJ19) cell line was a gift from Dr. Qiang Chen (Wuhan University). U2OS cells were cultured in McCoy's 5A (Pricella, PM150710) and others were cultured in DMEM (Gibco, C11995500CP) medium containing 10% fetal bovine serum (NEWZERUM, FBS-S500) and 1% penicillin–streptomycin (10 000 U/mL; Gibco,15 140-122) at 37°C in 5% (<i>v/v</i>) CO<sub>2</sub>.</p></sect2><sect2 id="sec2-3"><ti title="Heading 2">Constructs, antibodies, and reagents</ti><p t="fl" title="Paragraph No Indent">The cDNAs of <i>PRRX1A</i> and <i>PRRX1B</i> were subcloned into the pEGFP-C1, pmCherry-C1, pHAGE-zsgreen/puro, pMAL-c2X and pET-28a (+) vectors for expression of N-terminus-tagged or C-terminus-tagged fusion proteins. The cDNAs of Ku70 and Ku80 were cloned in to pGEX-4T-1 for recombinant protein expression and purification. All deletion and point mutants used in this study were generated by PCR and confirmed by DNA sequencing.</p><p t="i" title="Paragraph Indented">Primers for constructs and antibodies used in the study is listed in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S3</url>. Etoposide (E1383), CPT (C9911), Thymidine (T1895) and Polybrene (TR-1003) were purchased from Sigma-Aldrich (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_008 988). Puromycin (S7417), KU55933 (S1092), NU7441 (S2638) and Olaparib (S1060) were purchased from Selleckchem (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_003 823). Mirin (HY-117693) was purchased from MedChemExpress (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_025 062).</p></sect2><sect2 id="sec2-4"><ti title="Heading 2">shRNAs, lentivirus production and cell transfection</ti><p t="fl" title="Paragraph No Indent">For transient expression, cells were transfected with expression vectors using PEI (Sigma, 919 012) according to the manufacturer's instructions. Short-hairpin RNAs (shRNAs) targeting human <i>XRCC6</i> (Ku70) and a nontargeting control (Scramble) were cloned into pLKO.1 vector for stable expression. Lentiviral-based constructs were co-transfected with packaging plasmids pMD2.G and psPAX2 into HEK293T cells for subsequent harvest and stable gene expression. U2OS and Hs746T cells were transduced with lentivirus encoding shRNAs in the presence of 5 μg/mL Polybrene (1 000 ×) and selected with 2.5 μg/mL puromycin. Target-sequence information of the shRNAs was listed in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S3</url>.</p></sect2><sect2 id="sec2-5"><ti title="Heading 2">Modified DNA substrates</ti><p t="fl" title="Paragraph No Indent">All oligos shown in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S3</url> for DNA pull-down or MST assay were synthesized by Sangon Biotech. The blunt and overhang dsDNA (biotinylated or 6-FAM-labelled) were prepared by annealing complementary oligos in a PCR machine (BIO-RAD C-1000 Thermal Cycler; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_019 688): heating for 3 min to 95°C, then gradually cooling over a period of 45 min to room temperature (RT).</p><p t="i" title="Paragraph Indented">For DNA pull-down assay, Oligo#2-S was used as the single-stranded DNA (ssDNA) substrate, while the blunt double-stranded DNA (dsDNA) was formed by annealing Oligo#1-S with Oligo#1-A. The 3′ overhang DNA was formed by annealing Oligo#1-A with Oligo#2-S, and 5′ overhang DNA ormed by annealing Oligo#1-S with Oligo#2-A. In the MST assay, the blunt dsDNA was formed by annealing Oligo#3-S with Oligo#1-A, while dsDNA with various lenthgs of 5′ overhang was generated by annealing Oligo#3-S with Oligo#4-A, Oligo#5-A or Oligo#6-A.</p></sect2><sect2 id="sec2-6"><ti title="Heading 2">Peptides</ti><p t="fl" title="Paragraph No Indent">All peptides were synthetized by GenScript (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:SCR_002891">RRID:SCR_002891</url>; Nanjing, China). <query><button type="button" title="AU: Please note that the URL 'https://www.sciencedirect.com/topics/neuroscience/synthetic-peptide' is not valid/accessible. Please check and include a working URL directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="12" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">12</span></button></query><url title="URL" type="uri" href="https://www.sciencedirect.com/topics/neuroscience/synthetic-peptide">Synthetic peptides</url> were purified to &gt; 95% purity by high-pressure <query><button type="button" title="AU: Please note that the URL 'https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/liquid-chromatography' is not valid/accessible. Please check and include a working URL directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="13" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">13</span></button></query><url title="URL" type="uri" href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/liquid-chromatography">liquid chromatography</url>. Peptides were dissolved in ultrapure water to generate a 10 μg/μL stock solution and worked at a moderate concentration (40 μM) for experiments in cell. The peptides contain Biotin and a TAT sequence at their N-termini as follows: competing peptide, Biotin-GRKKRRQRRR-QALERVFER; mutated peptide, Biotin-GRKKRRQRRR-AALAAVFAA.</p></sect2><sect2 id="sec2-7"><ti title="Heading 2">Irradiation, laser micro-irradiation and live imaging</ti><p t="fl" title="Paragraph No Indent">Ionizing radiation (IR) was delivered to cells using an X-ray generator machine (160 KV, 25 mA, 1.2 Gy/min, Rad Source RS2000Prox). MOVAS, U2OS and Hs746T cells were seeded on glass-bottom dishes (NEST, 801 001) and transfected with the indicated plasmid using PEI 24 h prior to irradiation. Laser micro-irradiation (LMI) was performed using the MicroPoint Laser Illumination and Ablation System (Andor iQ; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_014 461) with a 337 nm laser (3.4 mW) generating a 365 nm UVA laser to induce DNA breaks in nuclei. Cells were either imaged live or fixed with 4% paraformaldehyde (PFA) for antibody staining. Images were captured using an Olympus IX71 microscope (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_022 185). GFP fluorescence at the laser stripe was analyzed with ImageJ, and the relative intensity (background-to-stripe ratio) was calculated for each time point and expressed as mean ± SEM.</p></sect2><sect2 id="sec2-8"><ti title="Heading 2">Immunofluorescence</ti><p t="fl" title="Paragraph No Indent">Cells were cultured on coverslips prior to experiments. For γH2AX staining, cells were fixed with 4% PFA at RT for 15 minutes and washed twice with PBS. For 53BP1 and pS2056 DNA-PKcs staining, cells were pre-extracted on ice for 5 minutes using pre-extraction buffer (20 mM HEPES, pH 7.4, 20 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.5% NP-40, 1 mM DTT, and protease inhibitor cocktail), followed by fixation with 4% PFA and blocking at RT for 30 minutes. Primary antibodies were diluted in TBST with 5% BSA and incubated overnight at 4°C. After washing, secondary antibodies diluted in blocking buffer were applied for 1 h at RT. Cells were washed twice and stained with DAPI (1:1 000 in PBS) or PicoGreen (1:500 in PBS) for 5 minutes at RT. After final washes, cells were mounted with antifade solution and imaged using a Leica Stellaris 5 WLL confocal microscope (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_024 663). All washes were performed in PBS, and blocking was done in NGS buffer (3% normal goat serum, 10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% Triton X-100, and 0.1% BSA).</p></sect2><sect2 id="sec2-9"><ti title="Heading 2">Affinity purification and mass spectrometry (AP-MS)</ti><p t="fl" title="Paragraph No Indent">Glioma-initiating cells (GICs) stably overexpressing FLAG-PRRX1A or FLAG-PRRX1B (the bait) were lysed with RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5% sodium deoxycholate, and 1% NP-40) on ice for 20 min. U2OS cells transiently overexpressing FLAG-PRRX1A were lysed using ice-cold lysis buffer (10 mM HEPES-NaOH, pH 8.0, 10 mM KCl,1.5 mM MgCl<sub>2</sub> and 0.5 mM β-mercaptoethanol) supplemented with protease inhibitor for 15 min, followed by the addition of 0.2% NP-40 for 2 minutes. After centrifugation (16 000 × <i>g</i> for 10 min at 4°C; Eppendorf 5810R; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_019 855), pellets were washed twice with cold PBS and resuspended in RIPA buffer. Each lysate was centrifuged again at 16 000 × <i>g</i> for 15 minutes, and the supernatants were incubated with anti-FLAG affinity agarose gel (Bimake, B23012) overnight at 4°C. The resin was washed five times with lysis buffer, and the proteins bound to the beads were eluted at 95°C for 5 minutes with SDS loading buffer. Eluted proteins were identified by mass spectrometry. Each bait was processed independently and analyzed alongside empty vector negative controls (cells expressing no bait), which were grown in parallel and treated identically to the bait-expressing cells.</p></sect2><sect2 id="sec2-10"><ti title="Heading 2">Immunoblotting and immunoprecipitation</ti><p t="fl" title="Paragraph No Indent">For immunoblotting, cells were directly lysed with 1 × SDS loading buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.01% bromophenol blue, and 1% β-mercaptoethanol) and heated at 95°C for 10 minutes. The supernatants were then loaded onto an SDS-polyacrylamide gel (SDS-PAGE) and immunoblotted using the indicated antibodies (primary antibody: diluted in 5% BSA TBST buffer; secondary antibody: diluted in 5% milk TBST buffer). Protein signals were detected using Western ECL Substrate (BIO-RAD) and captured on medical X-ray film.</p><p t="i" title="Paragraph Indented">For immunoprecipitation, cells were lysed with IP buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, and 1% NP-40) supplemented with a protease inhibitor cocktail for 15 minutes on ice. Whole cell lysates were centrifuged at 12 000 × <i>g</i> for 10 minutes. The supernatants were incubated with anti-FLAG beads or anti-PRRX1, anti-Ku70, anti-Ku80, and anti-DNA-PKcs antibodies, along with Protein A/G magnetic beads (Bimake, B23202), overnight at 4°C. After incubation, the beads were washed three times with IP buffer. The bound proteins were eluted with 2 × SDS loading buffer, heated at 95°C for 10 minutes, loaded onto an SDS-PAGE gel, and immunoblotted with the indicated antibodies.</p><p t="i" title="Paragraph Indented">For G1/S synchronization, U2OS cells were treated with 2.5 μM thymidine for 16 h, washed three times with PBS, and cultured with fresh medium for 8 h. Cells were then treated with 2.5 μM thymidine for another 16 h to allow cells to be blocked in the G1/S phase. For M phase synchronization, U2OS cells were treated with 0.1 μg/mL colchicine (Beyotime, ST-1173) for 12 h.</p></sect2><sect2 id="sec2-11"><ti title="Heading 2">Sucrose density gradient centrifugation (SDGC)</ti><p t="fl" title="Paragraph No Indent">To isolate and confirm the endogenous protein complexes associated with PRRX1, SDGC assay was performed following published protocol [<bibcit rid="bib35" title="bibcit" href="#" contenteditable="false" id="link_d3e67960" sno="35">35</bibcit>]. A linear gradient was prepared using 10% and 40% (<i>w/w</i>) sucrose solutions with the BioComp Gradient Master (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_025 583). Cells were lysed with SDGC lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 250 mM sucrose, and 0.5% NP-40) supplemented with a protease inhibitor cocktail for 15 minutes on ice. After centrifugation at 12 000 × <i>g</i> for 5 minutes at 4°C, the supernatants (input) were loaded onto the sucrose gradient. Ultracentrifugation was performed using an SW40T rotor (Beckman; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_025 331) at 100 000 × <i>g</i> for 16 h at 4°C. Aliquots from each fraction were analyzed by SDS-PAGE and immunoblotting to visualize the components.</p></sect2><sect2 id="sec2-12"><ti title="Heading 2">Chromatin fractions extraction</ti><p t="fl" title="Paragraph No Indent">Following a previously described method with slight modifications [<bibcit rid="bib36" title="bibcit" href="#" contenteditable="false" id="link_d3e70361" sno="36">36</bibcit>], cytoplasmic soluble fractions were obtained using ice-cold lysis buffer (10 mM HEPES-NaOH, pH 8.0, 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, and 0.5 mM β-mercaptoethanol) supplemented with a protease inhibitor cocktail. Cells were lysed on ice for 15 minutes, followed by the addition of 0.2% NP-40 for 2 minutes. The lysates were centrifuged at 16 000 × <i>g</i> for 10 minutes at 4°C, and the pellets were washed at least twice with cold PBS. The washed pellets were resuspended in cold nuclei lysis buffer (10 mM Tris-HCl, pH 7.5, 300 mM NaCl, 2 mM MgCl<sub>2</sub>, 0.5% NP-40, and 1 mM DTT) and incubated for 10 minutes to extract soluble nuclear proteins. After centrifugation at 16 000 × <i>g</i> for 10 minutes at 4°C, the remaining pellets were treated with 0.25 M HCl and incubated overnight at 4°C to extract histone and chromatin-associated proteins. The following day, the samples were centrifuged at 16 000 × <i>g</i> for 10–15 minutes, and the supernatants were collected as chromatin fractions. To neutralize the HCl, 2.5 M NaOH was added to the chromatin fractions before separation by SDS-PAGE.</p></sect2><sect2 id="sec2-13"><ti title="Heading 2">Expression and purification of recombinant proteins</ti><p t="fl" title="Paragraph No Indent">Prokaryotic expression constructs of PRRX1 (pMAL-c2X and pET-28a) and Ku70/Ku80 (pGEX-4T-1) were transformed into the BL21 (DE3) E. coli strain. When bacterial cultures reached an OD<sub>600</sub> of 0.6–0.8, protein expression was induced with 0.2 mM IPTG at 25°C for 12 h (PRRX1) or 16°C for 18 h (Ku70/Ku80). Bacteria were lysed by sonication in lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, and 0.1% Triton X-100), and lysates were cleared by centrifugation at 4°C. Supernatants were incubated with Ni-IDA 6FF resin (20 mM imidazole), amylose resin, or glutathione agarose beads, depending on the tag. Beads were washed with 10 column volumes of lysis buffer, and proteins were eluted with buffer containing either 200 mM imidazole, 10 mM maltose, or 20 mM reduced glutathione. MBP-PRRX1 proteins were further purified using molecular sieve chromatography and dialyzed in buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10% glycerol). Proteins were concentrated using Amicon Ultra-4 filters, aliquoted, and stored at –80°C. Concentrations were estimated using SDS-PAGE stained with Coomassie blue.</p></sect2><sect2 id="sec2-14"><ti title="Heading 2"><i>In vitro</i> pull-down assay</ti><p t="fl" title="Paragraph No Indent">For the MBP pull-down assay, 2.5 μg of MBP or MBP-PRRX1 (PA/PB) was incubated with approximately 3 μg of GST or GST-Ku70/Ku80, 1 μg of His-Ku70/Ku80 heterodimer (Sino Biological, CT018-H07B), or 2 μg of His-PRRX1 (PA/PB) in 400 μL of NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.5 mM EDTA, and 0.5% NP-40) per sample at 4°C for 2 h. Amylose resin (20 μL) was added to capture the protein complex, followed by constant shaking for 2 h. The supernatant was removed, and the resin was washed at least three times with 800 μL of the same buffer. Bound proteins were eluted with 40 μL of 2 × SDS loading buffer, and eluates were analyzed by western blotting using the indicated antibodies.</p><p t="i" title="Paragraph Indented">For the DNA pull-down assay, pre-reactions were conducted in 200 μL of NETN buffer containing 0.1 μg/μL BSA, 20 pmol of biotinylated DNA substrate, and 25 μL of streptavidin agarose (Invitrogen, S951) at room temperature for 1 h. Subsequently, approximately 100 fmol of purified MBP or various MBP-tagged PRRX1 proteins were added, and samples were incubated at 4°C for 2 h. Beads were washed three times with 500 μL of buffer each time and boiled in SDS loading buffer at 95°C for 5 minutes for western blot analysis.</p></sect2><sect2 id="sec2-15"><ti title="Heading 2">Chromatin immunoprecipitation (ChIP)</ti><p t="fl" title="Paragraph No Indent">EJ5 U2OS cells were transfected with the indicated plasmids for 24 h or infected with lentiviruses expressing shRNAs for 48 h, followed by transfection with pCMV-I-SceI. After 24 h of incubation, cells were crosslinked with 1% formaldehyde and lysed in SDS-containing lysis buffer. The lysates were sonicated and subjected to immunoprecipitation using the indicated antibodies. Immunoprecipitated complexes were captured with protein A/G magnetic beads, and crosslinking was reversed by incubation at 65°C. Proteins were digested with proteinase K, and the DNA was purified. To analyze the damaged regions (the DSB site and a control site), the purified DNA was amplified using the indicated primers listed in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S3</url>.</p></sect2><sect2 id="sec2-16"><ti title="Heading 2">Electrophoretic mobility shift assay (EMSA)</ti><p t="fl" title="Paragraph No Indent">The indicated concentrations of MBP-PRRX1A, with or without dsDNA, were combined with 200 nM of unlabeled dsDNA (blunt, 54 bp) substrate in 20 μL of binding buffer containing 20 mM Tris-HCl (pH 7.4), 10 mM MgCl<sub>2</sub>, 2.5% glycerol, 0.05% NP-40, and 0.1 μg/μL BSA. After a 15-minute incubation at room temperature, the reactions were terminated by adding 4 μL of 6 × DNA loading buffer (NEB), resolved on a 3% agarose gel stained with ethidium bromide (EB), and analyzed using the BIO-RAD MP imaging instrument (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_019 037).</p></sect2><sect2 id="sec2-17"><ti title="Heading 2">Microscale thermophoresis (MST) assay</ti><p t="fl" title="Paragraph No Indent">Purified His-PRRX1A in optimized MST buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 2.5% glycerol, and 0.05% Tween 20) was mixed with 6-FAM-labeled dsDNA as previously described. After a 10-minutes incubation at room temperature, the reaction mixtures were enclosed in premium-coated glass capillaries and loaded into the Monolith NT.115 instrument (NanoTemper). Measurement procedures and Kd value analysis were conducted using the corresponding software MO.Control (v1.4.2).</p></sect2><sect2 id="sec2-18"><ti title="Heading 2">DNA-PK kinase- assay</ti><p t="fl" title="Paragraph No Indent">DNA-PK activity was assessed using a DNA-PK kinase kit (Promega, V4106) following the manufacturer's protocol and incorporating slight modifications based on prior studies [<bibcit rid="bib16" title="bibcit" href="#" contenteditable="false" id="link_d3e77162" sno="16">16</bibcit>,<bibcit rid="bib26" title="bibcit" href="#" contenteditable="false" id="link_d3e77463" sno="26">26</bibcit>]. The kinase reaction system included DNA-PK kinase enzyme, reaction buffer, activation buffer (containing 100 μg/mL CT-DNA), a mixture of γ-<sup>32</sup>P-ATP (10 mCi/mL; PerkinElmer, NEG502A100UC) and cold ATP (Solarbio, A9130), and recombinant C-MYC protein (HCUSABIO, CSB-EP015270HU) as the substrate. Each reaction contained the DNA-PK holoenzyme in a solution comprising 1 μL ATP mixture (with 2 μCi γ-<sup>32</sup>P-ATP), 10 ng/μL CT-DNA, 1.5 μg C-MYC, 100 U DNA-PK kinase (∼0.8 μL), and different purified MBP-tagged PRRX1 proteins (∼0.2 μM). The reaction mixture was incubated at 30°C for 15 min, diluted with 5 × SDS loading buffer, boiled at 95°C for 5 min, and analyzed on an SDS-PAGE gel. DNA-PK activity was quantified as the band signal of <sup>32</sup>P-labeled C-MYC on the dried gel using the GE Typhoon FLA9500 phosphoimager (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_019 946).</p></sect2><sect2 id="sec2-19"><ti title="Heading 2">NHEJ and HR reporter assays</ti><p t="fl" title="Paragraph No Indent">NHEJ and HR reporter assays were conducted following previously established protocols [<bibcit rid="bib37" title="bibcit" href="#" contenteditable="false" id="link_d3e79564" sno="37">37</bibcit>]. U2OS cells were treated with 2 μM NU7441 or 5 μM Olaparib for 6 h. Subsequently, 2 μg of linearized reporter plasmids, either pimEJ5GFP (miaolingbio, P31613; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> Addgene_44 026) or pDRGFP (a gift from Dr. Pingkun Zhou; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> Addgene_26 475), digested with I-SceI meganuclease (NEB, R0694S), were co-transfected with 0.4 μg of either an empty vector (expressing mCherry) or mCherry-PRRX1 constructs into cells plated in 6-well plates. After 24 h, cells were harvested, and GFP-positive cells were quantified using the BD LSRFortessa X-20 Cell Analyzer (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_025 285). The relative repair efficiency was calculated as the proportion of GFP/mCherry double-positive cells to total mCherry-positive cells. Data represent the means of at least three independent experiments.</p></sect2><sect2 id="sec2-20"><ti title="Heading 2">Cell survival assay</ti><p t="fl" title="Paragraph No Indent">Hs746T cells were infected with shPRRX1 lentivirus for 48 h, trypsinized, and seeded at density of 3 × 10<sup>3</sup>/well in 96-well plates and exposed to IR. MEFs were seeded in 96-well plates at density of 10<sup>3</sup>/well for 24 h and exposed to increasing doses of Etoposide, CPT or IR. After 96 h, cell survival was performed using the CCK-8 Kit (Beyotime, C0038) and Molecular Devices SpectraMax iD3 microplate reader (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_023 920). Cells without treatment were used as controls. The survival fraction was calculated as OD450 [ (sample blank)/ (control blank)]. Results are presented as the mean ± SEM from at least three independent experiments.</p></sect2><sect2 id="sec2-21"><ti title="Heading 2">Metaphase spread</ti><p t="fl" title="Paragraph No Indent">MEFs were incubated with 0.1 μg/mL colchicine at 37°C for 4 h, then collected and swollen in prewarmed 75 mM KCl at 37°C for 20 min. After centrifugation, the cells were fixed with Carnoy's buffer (3:1 methanol: acetic acid) at room temperature for 10 minutes. The cells were centrifuged for 4 minutes at 1 000 × <i>g</i> and the supernatant was aspirated. The cells were resuspended in Carnoy's buffer twice. The cell suspension was dropped onto slides and dried for at least 15 min. Slides were stained with Wright Giemsa solution (20 ×; Beyotime, C0131), and genomic instability was assessed by counting cells with chromosomal breaks.</p></sect2><sect2 id="sec2-22"><ti title="Heading 2">RNA isolation and RT-qPCR</ti><p t="fl" title="Paragraph No Indent">Total RNA from MEFs or U2OS cells was isolated using RNAiso Plus (TAKARA, 9109) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed into cDNA using HiScript II Q RT SuperMix (Vazyme, R222-01). The resulting cDNA was then analyzed by quantitative RT-PCR (qRT-PCR) using SYBR Green qPCR Mix (Monad, MQ00801S). The amplification protocol consisted of an initial denaturation at 95 °C for 5 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 20 s. Gene expression levels were normalized to the Ct values of Gapdh or ACTB (control) using the 2<sup>−ΔΔCt</sup> method. Reactions were conducted on a BIO-RAD CFX Connect™ Real-Time PCR Detection System (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:SCR_018064">RRID:SCR_018064</url>). Primer sequences for the qPCR are listed in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S3</url>. RNA sequencing of MEFs was performed and analyzed by Novogene (Beijing, China).</p></sect2><sect2 id="sec2-23"><ti title="Heading 2">wGII, genomic scar signature and survival analyses</ti><p t="fl" title="Paragraph No Indent">Allele-specific segmented copy number data, clinical survival data, and PRRX1 RNA expression data (log-transformed transcripts per million, TPM) from the TCGA STAD cohort were downloaded using the R package TCGAbiolinks (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_017 683). The samples were categorized based on the median <i>PRRX1</i> expression level. The weighted genome instability index (wGII) for all samples was recalculated following previous studies [<bibcit rid="bib38" title="bibcit" href="#" contenteditable="false" id="link_d3e85565" sno="38">38</bibcit>,<bibcit rid="bib39" title="bibcit" href="#" contenteditable="false" id="link_d3e85866" sno="39">39</bibcit>]. Genomic scars (LOH, TAI, and LST) were calculated using the R package scarHRD (v0.1.1), based on relevant studies [<bibcit rid="bib40" title="bibcit" href="#" contenteditable="false" id="link_d3e86167" sno="40">40</bibcit>,<bibcit rid="bib41" title="bibcit" href="#" contenteditable="false" id="link_d3e86568" sno="41">41</bibcit>]. Statistical significance was assessed using the two-sided Wilcoxon rank-sum test (Mann-Whitney U test). Overall survival analysis for gastric cancer cases (n = 531) was conducted using the best cut-off method on Kaplan-Meier Plotter (<url title="URL" type="uri" href="https://kmplot.com/analysis/">https://kmplot.com/analysis/</url>; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_018 753). For samples with radiotherapy information (n = 78), grouping was performed based on <i>PRRX</i>1 expression levels. Survival differences among groups were assessed using TCGAanalyze_survival, and visualizations were generated using R v4.2 (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_001 905).</p></sect2><sect2 id="sec2-24"><ti title="Heading 2">Protein structure prediction and docking</ti><p t="fl" title="Paragraph No Indent">The predicted structural model of human PRRX1 (model: AF G3V2N3 F1) was downloaded from the AlphaFold Protein Structure Database (<url title="URL" type="uri" href="https://alphafold.ebi.ac.uk">https://alphafold.ebi.ac.uk</url>; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_023 662) [<bibcit rid="bib42" title="bibcit" href="#" contenteditable="false" id="link_d3e89169" sno="42">42</bibcit>], and docked with the structures of dsDNA (PDB: 5J3G) or the SAP domain of human Ku70 (PDB: 1JJR) from the RCSB PDB (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_008 227) as ligands using the ClusPro 2.0 webserver (<url title="URL" type="uri" href="https://cluspro.bu.edu/login.php">https://cluspro.bu.edu/login.php</url>; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_018 248) [<bibcit rid="bib43" title="bibcit" href="#" contenteditable="false" id="link_d3e90470" sno="43">43</bibcit>]. The docking results were analyzed and prepared for figures in UCSF ChimeraX-1.7 (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_015 872) [<bibcit rid="bib44" title="bibcit" href="#" contenteditable="false" id="link_d3e91071" sno="44">44</bibcit>].</p></sect2><sect2 id="sec2-25"><ti title="Heading 2">Statistics and reproducibility</ti><p t="fl" title="Paragraph No Indent">All statistical analyses were performed using GraphPad Prism (v.10.0) (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_002 798) or Microsoft Excel 2019 (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_016 137). Statistical significance was determined using two-tailed Student's t test or ANOVA, as appropriate. A <i>P</i>-value of &lt; 0.05 was considered significant. The number of cells or replicates (<i>n</i>) for each experiment is indicated in the figures or legends. Data for bar and line graphs are presented as mean ± SEM unless otherwise specified in the legends. Immunofluorescence micrographs are representative of at least two independent experiments using the indicated cells with the same treatment. Western blot data were obtained from the respective experiment, processed in parallel, and are representative of three independent experiments unless otherwise noted in the legends.</p></sect2></sect1><sect1 id="sec3" sec-type="results"><ti title="Heading 1">Results</ti><sect2 id="sec3-1"><ti title="Heading 2">PRRX1 interacts with Ku70 <i>in vitro</i> and <i>in vivo</i></ti><p t="fl" title="Paragraph No Indent">The HD transcription factor PRRX1 plays a pivotal role in mesodermal development and is implicated in various cancers. In glioblastoma, PRRX1 promotes propagation of glioma-initiating cells (GICs), as well as tumor invasion and angiogenesis [<bibcit rid="bib45" title="bibcit" href="#" contenteditable="false" id="link_d3e94372" sno="45">45</bibcit>,<bibcit rid="bib46" title="bibcit" href="#" contenteditable="false" id="link_d3e94673" sno="46">46</bibcit>]. To gain a comprehensive understanding of PRRX1’s functions, we sought to identify its associated proteins. We performed affinity purification of PRRX1 using GICs stably expressing Flag epitope-tagged PRRX1 isoforms - PRRX1A or PRRX1B - and carried out mass spectrometry (AP-MS) analysis. Unexpectedly, we found that several NHEJ factors, including Ku70 (encoded by <i>XRCC6</i>), Ku80 (encoded by <i>XRCC5</i>), and DNA-PKcs (encoded by <i>PRKDC</i>), are among the top hits (Fig. <figcit rid="fig1" title="figcit" href="#" contenteditable="false" id="link_d3e95974" sno="1">1</figcit>A; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S1</url>). Of note, none of the HR components were identified through AP-MS. We then repeated the AP-MS analysis in untreated or DNA-damaged U2OS cells overexpressing Flag-tagged PRRX1A. Consistently, several DDR factors, particularly those involved in the NHEJ, as well as chromatin associated proteins, were identified as PRRX1-associated proteins (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S1</url>A, B and <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S1</url>). To validate the AP-MS data, we first performed co-immunoprecipitation (co-IP) experiments in HEK293T cells transiently transfected with plasmids expressing Flag-tagged PRRX1A/B. As shown in <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S2</url>A to <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S2</url>C, PRRX1 interacted with all three components of the DNA-PK complex, Ku70, Ku80, and DNA-PKcs. Previous studies have indicated that the association between DNA-PKcs and the Ku70/Ku80 heterodimer is DNA dependent [<bibcit rid="bib47" title="bibcit" href="#" contenteditable="false" id="link_d3e97875" sno="47">47</bibcit>]. However, we revealed that the addition of DNase I did not disrupt the interaction between PRRX1 and the DNA-PK complex (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S2</url>B), suggesting that this interaction is DNA-independent. We next carried out reciprocal co-IP assay in MOVAS cells and verified the endogenous interactions between PRRX1, Ku70/80 and DNA-PKcs (Fig. <figcit rid="fig1" title="figcit" href="#" contenteditable="false" id="link_d3e98476" sno="1">1</figcit>B, C; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S2</url>D). Notably, the the association between PRRX1 and the DNA-PK complex is cell cycle independent (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S2</url>E). Moreover, sucrose gradient fractions of U2OS and MEF cell extracts showed that a substantial portion of Ku70/80 and DNA-PKcs sedimented with PRRX1 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S2</url>F, G). Thus, we identified PRRX1 as a novel interacting partner of the DNA-PK complex, suggesting a potential role for PRRX1 in NHEJ.</p><fig id="fig1" prefix="Figure" suffix="." sno="1" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="1" type="arabic" sub-type="">PRRX1 interacts with Ku70. <b>(A)</b> Proteins identified by immunoprecipitation (IP) of FLAG-PRRX1 followed by mass spectrometric (MS) in glioblastoma cells. Components of the NHEJ core complex are listed, with PRRX1 indicated in red letters. <b>(B, C)</b> Lysates of irradiated MOVAS cell were precipitated with anti-PRRX1 <b>(B)</b> or anti-Ku70 <b>(C)</b> antibodies followed by immunoblotting (IB) with indicated antibodies. <b>(D, E)</b> MBP pull-down assays using recombinant MBP-tagged PRRX1A (MBP-PA) to co-purify His-tagged Ku70/80 heterodimer <b>(D)</b> and GST-tagged Ku70 or Ku80 <b>(E)</b>. Co-purified products were immunoblotted with indicated antibodies. <b>(F)</b> The diagram depicting the long (PRRX1B, PB) and short (PRRX1A, PA) isoforms of PRRX1 along with PRRX1A’s mutants and truncations. Numbers indicate amino acid residues. OAR: the otp/aristaless/rax domain. <b>(G)</b> MBP pull-down assays using MBP-tagged PRRX1A truncations to co-purify GST-Ku70. Co-purified products were immunoblotted with indicated antibodies. All experiments were performed for at least three times and representative blots were shown<query><button type="button" title="AU: Figures have been edited to conform to journal style. Please check all figures carefully. If any adjustments are needed, where possible please note these as instructions to the typesetter rather than providing a replacement figure." contenteditable="false" query-type="open" roleid="12" conversation-uid="14" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">14</span></button></query>.</ti><img src="gkaf2001_f1.jpg" title="Figure"></img></fig><p t="i" title="Paragraph Indented">To explore whether PRRX1 directly binds to Ku70/80 or DNA-PKcs, we examined the interactions between purified MBP-PRRX1 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>A) and recombinant Ku70 and Ku80 proteins (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>B), or Ku70/80 and DNA-PKcs in lysates derived from the wild-type or Ku80 knockout CHO cells (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>C). The results showed that PRRX1 specifically interacts with Ku70 but not with Ku80 or DNA-PKcs (Fig. <figcit rid="fig1" title="figcit" href="#" contenteditable="false" id="link_d3e104477" sno="1">1</figcit>D, E; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>C).</p></sect2><sect2 id="sec3-2"><ti title="Heading 2">The PRRX1 NRR motif and Ku70 SAP domain are crucial for mediating the PRRX1-Ku70 interaction</ti><p t="fl" title="Paragraph No Indent">We next identified the specific region of PRRX1 required for its interaction with Ku70. A serials of MBP-fused PRRX1 truncations and mutations were generated, including the C-terminus-deleted PRRX1A (ΔC), the N-terminal region (N), the HD, and a mutant with conserved residues Asn144/Arg145/Arg146 altered (NRR<sup>Mut</sup>), (Fig. <figcit rid="fig1" title="figcit" href="#" contenteditable="false" id="link_d3e105878" sno="1">1</figcit>F). Pull-down assays revealed that the Ku70-binding capacity of PRRX1 depends on its HD and N-terminal region. Specifically, only the full-length and the C-terminus-deleted (ΔC) PRRX1A could bind to Ku70, while the NRR<sup>Mut</sup> mutant failed to do so (Fig. <figcit rid="fig1" title="figcit" href="#" contenteditable="false" id="link_d3e106479" sno="1">1</figcit>G). Thus, the conserved NRR motif within the HD domain of PRRX1 is crucial to mediate its interaction with Ku70. Interestingly, the ΔC exhibited a higher affinity to GST-Ku70 than the full-length PRRX1, implying that the C-terminal region might limit its ability to bind Ku70. Moreover, the docking between PRRX1 and Ku70/80 showed that Asn144/Arg146 constitutes the interaction interface with the SAP domain of Ku70 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>D). Concordantly, MBP pull-down assays revealed that neither PRRX1A<sup>N144A</sup> nor PRRX1A<sup>R146A</sup> could associate with Ku70/80 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>E). To determine the PRRX1-interacting domain of Ku70, we generated a series of GST-tagged Ku70 truncations and performed pull-down assays (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>F). Notably, our investigation revealed that among various segments of Ku70, only the C-terminal SAP (C-SAP) domain possesses the capability to bind to PRRX1 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S3</url>G). Collectively, PRRX1 interacts with Ku70 both <i>in vitro</i> and <i>in vivo</i>, with the interaction likely mediated by the NRR motif of PRRX1 and the SAP domain of Ku70.</p></sect2><sect2 id="sec3-3"><ti title="Heading 2">PRRX1 rapidly translocates onto DNA damage sites</ti><p t="fl" title="Paragraph No Indent">Next, we investigated whether PRRX1 could be recruited to DNA lesions. Laser micro-irradiation (LMI) followed by immunofluorescence in MOVAS cells revealed that endogenous PRRX1 accumulated at damaged tracks marked by γH2AX, an indicator of the DNA damage (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e109880" sno="2">2</figcit>A). We conducted live cell imaging on U2OS cells expressing EGFP-PRRX1A/B to delineate the dynamics of PRRX1 recruitment to DNA damage sites. The results demonstrated that the recruitment of PRRX1 to DNA damage sites is rapid, reaching its peak at 2 minutes after LMI (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e110181" sno="2">2</figcit>B, C). We next studied the impact of various DSB factors, including PARP1, 53BP1, Ku70, DNA-PKcs, ATM and the MRN complex [<bibcit rid="bib48 bib49 bib50" title="bibcit" href="#" contenteditable="false" id="link_d3e110482" sno="48 49 50">48–50</bibcit>, <bibcit rid="bib51" title="bibcit" href="#" contenteditable="false" id="link_d3e110783" sno="51">51</bibcit>], on PRRX1 accumulation at DNA damage sites. These proteins can initiate downstream signaling cascades leading to the activation of NHEJ repair pathways. However, our findings indicated that shRNA-mediated knockdown of Ku70 (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e111084" sno="2">2</figcit>D), inhibition of PARP1, DNA-PK, ATM or the MRN complex (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S4</url>A), or deletion of 53BP1 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S4</url>B), did not affect the recruitment of PRRX1 to DNA damage sites. These findings indicate that PRRX1 recruitment at DNA damage sites is independent of PARP1, Ku70, DNA-PK or ATM, suggesting that it acts in the very early stage of DNA damage recognition and response. Notably, the recruitment kinetics of EGFP tagged PRRX1 to DNA damage sites were almost identical to those of EGFP-Ku70 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S4</url>C).</p><fig id="fig2" prefix="Figure" suffix="." sno="2" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="2" type="arabic" sub-type="">PRRX1 accumulates at DNA damage sites and directly binds to dsDNA. <b>(A)</b> MOVAS cells were subjected to laser micro-irradiation (LMI). Thirty minutes later, cells were fixed and subjected to immunofluorescence of anti-γH2AX and anti-PRRX1 antibodies. <b>(B)</b> U2OS cells were transfected with vectors expressing EGFP-PRRX1A/B and subject to LMI. Fluorescence images were collected at indicated time points. <b>(C)</b> Quantification of <b>(B)</b>. Data are presented as the mean fluorescence intensity change of irradiated stripes over background per cell (mean ± SEM). PRRX1A (PA), <i>n</i> = 20 cells; PRRX1B (PB), <i>n</i> = 20 cells. <b>(D)</b> Left: U2OS cells were transfected with vectors expressing mCherry-PRRX1B and shRNAs against Ku70 and subject to LMI. Fluorescence images were collected at indicated time points. Right: cell lysates at left were collected for immunoblotting of indicated antibodies. <b>(E)</b> DNA pull-downs of various forms of biotinylated (red asterisks) single-strand (ss) and double-strand (ds) DNAs with MBP, MBP-PRRX1A (PA) and PRRX1B (PB). Samples were immunoblotted with an anti-MBP antibody. <b>(F)</b> DNA pull-downs of blunt-end biotinylated dsDNA with various MBP-tagged PRRX1 mutants and truncations. <b>(G)</b> U2OS cells were transfected with vectors expressing various forms of EGFP-tagged PRRX1 mutants and truncations and were subjected to LMI. Fluorescence images were collected at indicated time points. <b>(H)</b> DNA pull-downs of biotinylated dsDNA with MBP and MBP-tagged PRRX1A mutants. Samples were immunoblotted with an anti-MBP antibody. All experiments were performed for at least three times and representative images/blots were shown. White triangles indicate irradiated tracks. Scale bars, 10 μm. s, seconds.</ti><img src="gkaf2001_f2.jpg" title="Figure"></img></fig></sect2><sect2 id="sec3-4"><ti title="Heading 2">PRRX1 binds to DNA in an NRR motif-dependent manner</ti><p t="fl" title="Paragraph No Indent">We then performed the biotinylated DNA pull-down using various forms of oligonucleotides with random sequences. MBP-PRRX1 exhibited a strong affinity to dsDNA with blunt ends, 3′ or 5′ overhangs, but showed no binding to single-strand (ss) DNA (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e116985" sno="2">2</figcit>E). It is worth noting that the shorter isoform, PRRX1A, demonstrated stronger DNA-binding affinity compared to the longer isoform, PRRX1B. Electrophoretic mobility shift assay (EMSA) and the microscale thermophoresis (MST) assay demonstrated the MBP-PRRX1A or His-PRRX1A binds to both blunt-ended dsDNA and 5′ overhang dsDNA with various overhang lengths (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S5</url>A, B). Importantly, only the full-length PRRX1A (MBP-PA) was captured by dsDNA. The NRR motif of PRRX1A, which is essential to mediate the interaction with Ku70, is also required for PRRX1’s binding to DNA, as the NRR<sup>Mut</sup> mutation completely abolished this capacity (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e117886" sno="2">2</figcit>F). In addition, PRRX1 truncation proteins lacking the C-terminus (ΔC) or retaining only the N-terminus (N) or the HD failed to bind DNA (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e118187" sno="2">2</figcit>F). Thus, full-length PRRX1 is required for DNA binding <i>via</i> the NRR motif. Consistently, LMI experiments showed that only the full-length EGFP-PRRX1A, but not its truncations or mutations, could be recruited to DNA lesions (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e118888" sno="2">2</figcit>G). These findings indicate that the NRR motif within the HD of PRRX1 is required for its DNA binding and accumulation at DNA damage sites.</p><p t="i" title="Paragraph Indented">Referring to the electrostatic potential map of human PRRX1 obtained from the AlphaFold Protein Structure Database [<bibcit rid="bib42" title="bibcit" href="#" contenteditable="false" id="link_d3e119389" sno="42">42</bibcit>], it is observed that the HD region possesses a negative electrostatic potential and interacts with the DNA major groove (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S5</url>C). Additionally, ClusPro docking simulation [<bibcit rid="bib43" title="bibcit" href="#" contenteditable="false" id="link_d3e119990" sno="43">43</bibcit>] revealed that the conserved residues Asn144/Arg145/Arg146, located at the helix α3 of HD, could bind to bases (by Asn144) and DNA backbone (by Arg145/Arg146) through hydrogen bonds, nonbonded electrostatic and hydrophobic interactions (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S5</url>D, E). Indeed, the DNA pull-down assay showed that PRRX1A<sup>N144A</sup> and PRRX1A<sup>R146A</sup> mutations reduced or abolished the interaction with dsDNA, respectively (Fig. <figcit rid="fig2" title="figcit" href="#" contenteditable="false" id="link_d3e121291" sno="2">2</figcit>H). Therefore, PRRX1 likely localizes to DNA breaks through directly binding to DNA. Interestingly, our results indicate that the NRR motif within the HD is essential for PRRX1’s interaction with both Ku70 and DNA.</p></sect2><sect2 id="sec3-5"><ti title="Heading 2">PRRX1 facilitates the recruitment and assembly of the DNA-PK complex on the chromatin</ti><p t="fl" title="Paragraph No Indent">Since PRRX1 can bind to both DNA and Ku70, we investigated whether PRRX1 affects Ku dynamics at damage sites and subsequent loading of DNA-PCcs. To this end, we examined DSB-induced recruitment of endogenous Ku70/80 and DNA-PKcs to chromatin in mouse embryonic fibroblasts (MEFs). MEFs were derived from <i>Prrx1</i>-knockout (KO) and wild-type (WT) embryos (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S6</url>A, B). Chromatin fractionation analysis revealed that the enrichment of Ku70/80 and DNA-PKcs on chromatin was markedly reduced in <i>Prrx1</i><sup>−/−</sup> cells compared to WT cells following Etoposide or ionizing radiation (IR) treatment (Fig. <figcit rid="fig3" title="figcit" href="#" contenteditable="false" id="link_d3e123192" sno="3">3</figcit>A, B; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S6</url>C, D). Conversely, in PRRX1-overexpressing U2OS cells, the chromatin enrichment of Ku70/80 and DNA-PKcs was markedly increased (Fig. <figcit rid="fig3" title="figcit" href="#" contenteditable="false" id="link_d3e123893" sno="3">3</figcit>C, D). LMI assays further showed that PRRX1 overexpression enhanced the recruitment of EGFP-Ku70 to DNA lesions (Fig. <figcit rid="fig3" title="figcit" href="#" contenteditable="false" id="link_d3e124194" sno="3">3</figcit>E, F). To further investigate the role of PRRX1 in Ku70 recruitment to DSB sites, we conducted chromatin immunoprecipitation (ChIP) analysis in EJ5 U2OS cells, where site-specific DSBs were induced by I-SceI digestion. ChIP assays were performed using antibodies against IgG, γH2AX, mCherry (for mCherry or mCherry-PRRX1A), or Ku70. The immunoprecipitated DNA was analyzed by quantitative PCR (qPCR) using primers targeting DSB and control sites, as illustrated in Fig. <figcit rid="fig3" title="figcit" href="#" contenteditable="false" id="link_d3e124495" sno="3">3</figcit>G. PRRX1 knockdown significantly decreased the enrichment of DNA fragments in Ku70 immunoprecipitants. In contrast, PRRX1 overexpression enhanced the enrichment of DNA fragments in Ku70 immunoprecipitants. Moreover, PRRX1 overexpression reversed the reduced enrichment of DNA fragments by anti-Ku70 antibodies. Taken together, PRRX1 promotes the loading of Ku70/80 and DNA-PKcs at DSB lesions.</p><fig id="fig3" prefix="Figure" suffix="." sno="3" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="3" type="arabic" sub-type="">PRRX1 facilitates the recruitment of Ku70/80 and the assembly of DNA-PK on chromatin. <b>(A, B)</b> WT and <i>Prrx1</i><sup>−/−</sup> MEF cells were treated with 5 Gy irradiation <b>(A)</b> or 10 μM ETP <b>(B)</b> at indicated time. Chromatin fractions (top) and whole cell lysates (bottom) were immunoblotted with indicated antibodies. <b>(C, D)</b> U2OS cells were transfected with empty vector (EV) or FLAG-PRRX1A for 36 h. Chromatin fractions (top) and whole cell lysates (bottom) were extracted at indicated time post 5 Gy irradiation <b>(C)</b> or 10 μM ETP <b>(D)</b> and subjected for immunoblotting with indicated antibodies. <b>(E, F)</b> U2OS cells were co-transfected with vectors expressing EGFP-Ku70 and pHAGE-PRRX1A (PA). After transfection, cells were subjected to LMI <b>(E)</b>. Scale bar, 10 μm. The relative fluorescent intensities of EGFP-Ku70 in cells of <b>(E)</b> were quantified. Data are mean ± SEM; 15 cells per each group were analyzed from two independent experiments <b>(F)</b>. Statistical analysis was performed using two-tailed unpaired <i>t</i>-tests. <b>(G)</b> Top: Diagram illustrating sites of DSBs and chromatin enrichment analyisis in EJ5 U2OS cells. Bottom: Cells were treated as indicated, followed by chromatin immunoprecipitation using indicated antibodies and subsequent qPCR. <b>(H, I)</b> U2OS cells were transfected with EV, FLAG-PRRX1A (PA), FLAG-NRR<sup>Mut</sup> <b>(H)</b>, EGFP-PRRX1A<sup>N144A</sup> and EGFP-ΔC <b>(I)</b>. Cell lysates were co-immunoprecipitated with anti-Ku70 antibody followed by immunoblotting with indicated antibodies. IB, immunoblotting. UT, untreated.</ti><img src="gkaf2001_f3.jpg" title="Figure"></img></fig><p t="i" title="Paragraph Indented">Next, we asked whether PRRX1 could facilitate the assembly of the DNA-PK complex. First, DNA pull-down assays demonstrated that blunt-end biotinylated dsDNA enriched more Ku70/80 and DNA-PKcs from lysates of PRRX1-overexpressing cells compared to control cells (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S6</url>G). Moreover, we noted that the presence of PRRX1 enhanced the association between Ku70/80 and DNA-PKcs, which was abolished if the Ku70- and DNA-binding NRR motif was mutated (Fig. <figcit rid="fig3" title="figcit" href="#" contenteditable="false" id="link_d3e131896" sno="3">3</figcit>H; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S6</url>E, F). Remarkably, both PRRX1<sup>N144A</sup> (retaining DNA- but not Ku70 binding) and ΔC (retaining Ku70- but not DNA binding) lost their abilities to facilitate the assembly of DNA-PK (Fig. <figcit rid="fig3" title="figcit" href="#" contenteditable="false" id="link_d3e132797" sno="3">3</figcit>I). Therefore, both Ku- and DNA-binding capacities of PRRX1 are required for stimulating the assembly of the DNA-PK complex on chromatin.</p></sect2><sect2 id="sec3-6"><ti title="Heading 2">PRRX1 stimulates the kinase activity of DNA-PK <i>in vitro</i> and <i>in vivo</i></ti><p t="fl" title="Paragraph No Indent">The DSB repair by NHEJ is initiated by the recognition and binding of the Ku70/80 heterodimer to broken DNA ends, which subsequently recruits DNA-PKcs and leads to its auto-phosphorylation at Ser2056 and Thr2609, a hallmark of NHEJ activation [<bibcit rid="bib52" title="bibcit" href="#" contenteditable="false" id="link_d3e134098" sno="52">52</bibcit>,<bibcit rid="bib53" title="bibcit" href="#" contenteditable="false" id="link_d3e134399" sno="53">53</bibcit>]. PRRX1, along with the cofactor FOXM1, was reported to activate the transcription of <i>PRKDC</i>, the gene encoding DNA-PKcs, in pancreatic cancer cells [<bibcit rid="bib34" title="bibcit" href="#" contenteditable="false" id="link_d3e1349100" sno="34">34</bibcit>]. However, <i>Prrx1</i><sup>−/−</sup> MEFs did not display significant alterations in mRNA levels of <i>Prkdc</i> and <i>Xrcc6</i> (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S7</url>B and <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Table S2</url>), and the protein level of DNA-PKcs only slightly decreased. Importantly, the phosphorylation levels of DNA-PKcs at Ser2056 post IR or ETP was strikingly decreased in <i>Prrx1</i><sup>−/−</sup> MEFs (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1376101" sno="4">4</figcit>A, B; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S7</url>A). As expected, levels of phosphorylated Ser2056 were modestly elevated in U2OS cells expressing Flag-tagged PRRX1A (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1382102" sno="4">4</figcit>C). Consistently, significantly fewer phosphorylated DNA-PKcs foci were detected in irradiated <i>Prrx1</i><sup>−/−</sup> MEFs than those in irradiated WT MEFs (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1390103" sno="4">4</figcit>D). Of note, the mRNA levels of <i>PRKDC</i> and <i>XRCC6</i> were not changed in PRRX1-overexpressing U2OS cells (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S7</url>D). To test whether PRRX1 could directly stimulate the activity of DNA-PK holoenzyme (Ku70/80 included), we performed kinase assays using purified His-tagged MYC as the phosphorylation substrate. As anticipated, the presence of dsDNA activated DNA-PK. Critically, the full-length PRRX1A significantly augmented MYC phosphorylation, whereas PRRX1 with mutated NRR or truncated C-terminus did not exhibit this effect (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1403104" sno="4">4</figcit>E).</p><fig id="fig4" prefix="Figure" suffix="." sno="4" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="4" type="arabic" sub-type="">PRRX1 activates DNA-PK to promote NHEJ. <b>(A, B)</b> WT and <i>Prrx1</i><sup>−/−</sup> MEF cells were treated with 5 Gy irradiation <b>(A)</b> or 10 μM ETP <b>(B)</b> and harvested at indicated times. Cell lysates were immunoblotted with indicated antibodies. <b>(C)</b> U2OS cells were transfected with EV or FLAG-PRRX1A (PA) for 36 h followed by treating with 10 μM ETP. Cell lysates were immunoblotted with indicated antibodies. <b>(D, F)</b> WT and <i>Prrx1</i><sup>−/−</sup> MEF cells were treated with 5 Gy irradiation for 1 h followed by immunofluorescence (top) and quantification (bottom) of phosphorylation at Ser2056 of DNA-PK <b>(D)</b> or 53BP1 <b>(F)</b> foci after irradiation. Statistical analysis was performed using two-tailed unpaired <i>t</i>-tests. Each point represents one cell; 100 cells quantified in each group were obtained from two independent experiments. Scale bars, 10 μm. <b>(E)</b> In the DNA-PK kinase assay, indicated components were mixed and the C-MYC protein was used as the substrate. Autoradiography and immunoblotting using indicated antibodies were performed. <b>(G)</b> Top: the diagram showing the EJ5-GFP reporter assay assessing the efficiency of NHEJ. Bottom: percentages of NHEJ (GFP<sup>+</sup>) cells were analyzed by flow cytometry and fold changes were normalized to cells transfected with empty mCherry-expressing vector. Data are mean ± SEM. Statistical analysis was performed using one-way ANOVA. <i>n</i> = 3 biologically replicates. <b>(H)</b> Top: the diagram showing the DR-GFP reporter assay assessing the efficiency of HR. Bottom: percentages of HR (GFP<sup>+</sup>) cells were analyzed by flow cytometry and fold changes were normalized to cells transfected with empty mCherry-expressing vector. Data are mean ± SEM. Statistical analysis was performed using two-tailed unpaired <i>t</i>-test. <i>n</i> = 6 biologically replicates.</ti><img src="gkaf2001_f4.jpg" title="Figure"></img></fig><p t="i" title="Paragraph Indented">The number of 53BP1 foci, the indicator of the NHEJ repair, was significantly reduced in irradiated <i>Prrx1</i><sup>−/−</sup> MEFs, suggesting impaired NHEJ in the absence of PRRX1 (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1481105" sno="4">4</figcit>F). Next, we employed the EJ5-GFPand DR-GFP reporter assays to directly assess the influence of PRRX1 on DSB repair <i>via</i> NHEJ or HR [<bibcit rid="bib54" title="bibcit" href="#" contenteditable="false" id="link_d3e1487106" sno="54">54</bibcit>]. As expected, knocking down the expression of PRRX1 compromised the NHEJ repair efficiency (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1490107" sno="4">4</figcit>G; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S7</url>C). Remarkably, PRRX1 overexpression led to a significant increase in NHEJ repair effeciency but had no effect on HR repair. Of note, the enhancement of NHEJ by PRRX1 overexpression was abolished by DNA-PK inhibitor NU7441 but only slightly affected by PARP1 inhibitor Olaparib (Fig. <figcit rid="fig4" title="figcit" href="#" contenteditable="false" id="link_d3e1497108" sno="4">4</figcit>G, H; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S7</url>D). Thus, PRRX1 facilitates the activation of DNA-PK to promote NHEJ repair.</p></sect2><sect2 id="sec3-7"><ti title="Heading 2">The oligomerization of PRRX1 is essential for the NHEJ repair</ti><p t="fl" title="Paragraph No Indent">As described earlier, PRRX1 binds to Ku70 or DNA <i>via</i> the same NRR motif in its HD domain. This prompt us to explore the possibility of PRRX1 oligomerization, which could enable simultaneous interaction with both Ku70 and DNA. We performed co-IP assays using extracts from HEK293T cells expressing Flag-PRRX1A/B and EGFP-PRRX1A/B, which revealed both homophilic and heterophilic interactions between PRRX1A and PRRX1B. Furthermore, we observed that these interactions were enhanced under IR and ETP conditions (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1511109" sno="5">5</figcit>A; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S8</url>A). Meanwhile, MBP pull-down assays showed that purified MBP-tagged PRRX1A/B could co-purify His-tagged PRRX1A/B (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1517110" sno="5">5</figcit>B). Furthermore, we observed that both PRRX1A and PRRX1B could form aggregates on native polyacrylamide gel electrophoresis (PAGE), with PRRX1A having a greater propensity for oligomer formation (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1520111" sno="5">5</figcit>C).</p><fig id="fig5" prefix="Figure" suffix="." sno="5" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="5" type="arabic" sub-type="">PRRX1 oligomerizes to mediate NHEJ repair. <b>(A)</b> HEK293T cells were co-expressed with EGFP-PRRX1A and FLAG-PRRX1A or FLAG-PRRX1B followed by 10 μM ETP treatment. Lysates were immunoprecipitated with anti-FLAG beads followed by immunoblotting with indicated antibodies. <b>(B)</b> MBP pull-down assays using recombinant MBP, MBP-PRRX1A/B (MBP-PA/PB) to co-purify His-PA and His-PB. Co-purified products were immunoblotted with indicated antibodies. <b>(C)</b> Native polyacrylamide gel electrophoresis (PAGE) of <i>in vitro</i> purified MBP-PA, MBP-PB (left), His-PA and His-PB (right). Black triangles indicate putative monomers and oligomers. <b>(D)</b> MBP pull-down assays using recombinant MBP, MBP-PA (WT), and indicated PA mutations to co-purify His-PA. Co-purified products were immunoblotted with indicated antibodies. <b>(E)</b> EJ5-GFP NHEJ reporter assays of U2OS cells overexpressing mCherry and mCherry-PA<sup>E110A/R111A</sup>. <i>n </i>= 4 biologically replicates. Statistical significance was determined by two-tailed unpaired <i>t</i>-test. <b>(F)</b> The table summarizing oligomer-forming, Ku- and DNA-binding capacities of various PRRX1 mutants and truncations. <b>(G)</b> MBP pull-down assays using recombinant MBP, MBP-PA, MBP-ΔC to co-purify His-PA and His-PA<sup>N144A</sup>. Co-purified products were immunoblotted with indicated antibodies. <b>(H)</b> U2OS cells were transfected with vectors expressing EGFP, EGGP-PA or EGFP-PA<sup>N144A</sup> with EGFP-ΔC and subjected to ETP treatment. Cell lysates were immunoprecipitated with anti-Ku70 antibody followed by immunoblotting with indicated antibodies. <b>(I)</b> EJ5-GFP reporter assays of U2OS cells overexpressing indicated vectors (mCherry tagged). <i>n </i>= 4 biologically replicates. Statistical analysis was performed using one-way ANOVA. <b>(J)</b> The diagram depicting a model in which PRRX1 oligomerizes through its α1 helix to facilitate simultaneous interactions with dsDNA and Ku70/80.</ti><img src="gkaf2001_f5.jpg" title="Figure"></img></fig><p t="i" title="Paragraph Indented">To investigate the regions of PRRX1 required for its oligomerization, we conducted MBP pull-down assays using a series of MBP-tagged PRRX1A truncations to co-purify His-tagged PRRX1A/B. We observed that the ΔN (94 – 217 aa) displayed reduced interaction with full-length PRRX1, whereas HD alone exhibited strong binding (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S8</url>B). Interestingly, the N-terminal region alone could not bind to PRRX1 (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S8</url>B), suggesting that both the N-terminal and the HD domain of PRRX1 are essential for the oligomeric formation. The molecular docking analysis predicted that several residues at the N-terminal helix α1 of the HD might be involved in the oligomerization (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S8</url>C). Next, point mutants of these residues were employed to assess their association with wild-type His-PRRX1A. The results revealed that PRRX1<sup>Q107A</sup> and PRRX1<sup>Q107A/E110A</sup> slightly reduced the interaction, while PRRX1<sup>E110A/R111A</sup> severely compromised the interaction (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1604112" sno="5">5</figcit>D). Consistently, PRRX1<sup>E110A/R111A</sup> lost the ability to promote DSB repair by NHEJ (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1610113" sno="5">5</figcit>E). Properties of oligomerization, Ku- and dsDNA-binding in all mutants and truncations were summarized in Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1613114" sno="5">5</figcit>F.</p><p t="i" title="Paragraph Indented">We further assessed the oligomeric capability of PRRX1A with mutations at conserved residues 144–146 of the HD. The results indicated that PRRX1A<sup>R145A</sup> and PRRX1A<sup>R146A</sup> barely interacted with wild-type PRRX1A, while PRRX1<sup>R145Q</sup>, identified in cancerous patients, and PRRX1<sup>N144A</sup> could bind to PRRX1A, with the latter exhibiting stronger association (<url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S8</url>D). To examine the impact of PRRX1 oligomerization on NHEJ, we studied the combination of PRRX1A<sup>N144A</sup> with ΔC, which respectively associate with dsDNA and Ku70. MBP pull-down assays revealed a strong interaction between PRRX1A<sup>N144A</sup> and ΔC (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1640115" sno="5">5</figcit>G). Co-IP experiments also revealed that like EGFP-PRRX1A alone, co-expression of EGFP-PRRX1A<sup>N144A</sup> and EGFP-ΔC augmented the association between Ku70 and DNA-PKcs (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1646116" sno="5">5</figcit>H). Importantly, NHEJ reporter assays demonstrated that while overexpressing PRRX1A<sup>N144A</sup> or ΔC alone had no effect on NHEJ efficiency, co-expressing PRRX1A<sup>N144A</sup> and ΔC could significantly enhance the NHEJ efficiency to a level comparable to full-length PRRX1A/B (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1656117" sno="5">5</figcit>I; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S8</url>E). In sum, by oligomerization mediated by the N-terminus of the HD, PRRX1 could simultaneously associate with Ku and dsDNA to facilitate NHEJ (Fig. <figcit rid="fig5" title="figcit" href="#" contenteditable="false" id="link_d3e1662118" sno="5">5</figcit>J).</p></sect2><sect2 id="sec3-8"><ti title="Heading 2">PRRX1 contributes to the maintenance of genome stability</ti><p t="fl" title="Paragraph No Indent">Having showed that PRRX1 facilitates recruitment of Ku70/80 to DSBs and promotes NHEJ, we proceeded to investigate whether PRRX1 plays a role in the DSB repair. Immortalized KO MEFs exhibited increased sensitivities to X-ray IR and several DNA-damaging agents, including the topoisomerase II inhibitor etoposide (ETP) and the topoisomerase I inhibitor camptothecin (CPT) (Fig. <figcit rid="fig6" title="figcit" href="#" contenteditable="false" id="link_d3e1670119" sno="6">6</figcit>A; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S9</url>A). WT and KO MEFs were treated with IR followed by γH2AX immunofluorescence to determine whether PRRX1 affects DNA repair efficiency. <i>Prrx1</i><sup>−/−</sup> MEFs displayed significant higher numbers of γH2AX foci at late time points (8 h and 24 h post IR), implying that the loss of PRRX1 impairs DSB repair (Fig. <figcit rid="fig6" title="figcit" href="#" contenteditable="false" id="link_d3e1681120" sno="6">6</figcit>B; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S9</url>B). Previous studies have shown that deficiency in DSB repair leads to persistent DNA damage, micronucleus formation, and leakage of damaged nuclear DNA into the cytoplasm, which activates the innate immune response [<bibcit rid="bib55" title="bibcit" href="#" contenteditable="false" id="link_d3e1688121" sno="55">55</bibcit>, <bibcit rid="bib56" title="bibcit" href="#" contenteditable="false" id="link_d3e1691122" sno="56">56</bibcit>, <bibcit rid="bib57" title="bibcit" href="#" contenteditable="false" id="link_d3e1694123" sno="57">57</bibcit>]. Notably, we observed that <i>Prrx1</i><sup>−/−</sup> MEFs had an increased frequency of chromosomal breaks, micronucleus, and cytosolic dsDNA compared with those from wild-type littermates (Fig. <figcit rid="fig6" title="figcit" href="#" contenteditable="false" id="link_d3e1702124" sno="6">6</figcit>C-E). Consequently, irradiated <i>Prrx1</i><sup>−/−</sup> MEFs displayed increased levels of phosphorylated TBK1, IRF3 and STING, indicating enhanced response to damaged DNA (Fig. <figcit rid="fig6" title="figcit" href="#" contenteditable="false" id="link_d3e1711125" sno="6">6</figcit>F; <url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Fig. S9</url>C). Together, these results underscore the crucial role of PRRX1 in promoting DSB repair <i>via</i> NHEJ, highlighting its significance in enhancing cellular resistance to genotoxic stress and maintaining genomic stability.</p><fig id="fig6" prefix="Figure" suffix="." sno="6" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="6" type="arabic" sub-type="">PRRX1 maintains genomic integrity. <b>(A)</b> Immortalized wild type (WT) and <i>Prrx1</i><sup>−/−</sup> MEF cells were treated with indicated doses of IR, Etoposide (ETP, 72 h) or CPT (72 h) and cell survival rates were analyzed by CCK-8 assays (<i>n </i>= 3 independent experiments). Data show the mean ± SEM and differences between two different groups were compared using the unpaired, two-tailed Student's <i>t</i>-test. <b>(B)</b> WT and <i>Prrx1</i><sup>−/−</sup> MEF cells were treated with 5 Gy irradiation followed by immunofluorescence (top) and quantification of γH2AX foci (bottom) at indicated time points. Data are mean ± 95% confidence interval (CI). Statistical analysis was performed using two-tailed unpaired <i>t-</i>tests. Each point represents one cell; 100 cells quantified in each group were obtained from two independent experiments. UT, untreated. Scale bars, 10 μm. <b>(C)</b> Irradiated WT and <i>Prrx1</i><sup>−/−</sup> MEF cells were measured with chromosome/chromatid breaks (magnification 1000 ×). Red boxes show representative breaks. The right chart indicates the quantification. <i>n </i>= 92 cells per genotype, pooled from three independent experiments. Solid lines show median values, and the whiskers extend from the minimum to maximum value. Statistical analysis was performed using two-tailed unpaired <i>t</i>-tests. <b>(D)</b> Representative DAPI images (left) and quantifications (right) of micronucleus in irradiated MEF cells. White arrows indicate the micronucleus. Data are mean ± SEM. Statistical analysis was performed using two-tailed unpaired <i>t</i>-tests. Scale bar, 25 μm. <b>(E)</b> Representative PicoGreen images (top) and quantifications (bottom) of cytoplasmic dsDNA in irradiated MEF cells. Data are mean ± SEM. Statistical analysis was performed using two-tailed unpaired <i>t</i>-tests. Each point represents one experiment; 200 cells quantified in each group were obtained from four independent experiments. Scale bar, 10 μm. <b>(F)</b> WT and <i>Prrx1</i><sup>−/−</sup> MEF cells were treated with 2 Gy irradiation and harvested at indicated times. Cell lysates were immunoblotted with indicated antibodies.</ti><img src="gkaf2001_f6.jpg" title="Figure"></img></fig></sect2><sect2 id="sec3-9"><ti title="Heading 2">Low expression and pathogenic mutation of PRRX1 are associated with genomic instability and defective NHEJ repair</ti><p t="fl" title="Paragraph No Indent">In cancer cells, dysregulated DDR mechanisms often lead to resistance or sensitivity to chemotherapy and radiotherapy [<bibcit rid="bib12" title="bibcit" href="#" contenteditable="false" id="link_d3e1794126" sno="12">12</bibcit>]. Having illustrated the roles and mechanisms of PRRX1 in NHEJ, we then examined how PRRX1 expression and mutations occurring in tumors could affect NHEJ. We analyzed the weighted genomic integrity index (wGII) [<bibcit rid="bib39" title="bibcit" href="#" contenteditable="false" id="link_d3e1797127" sno="39">39</bibcit>], a widely used signature of genomic instability, in stomach adenocarcinoma (STAD) samples from the TCGA database. The data revealed that tumors with low PRRX1 expression displayed higher wGII (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1800128" sno="7">7</figcit>A). Concordantly, STAD samples with lower PRRX1 expression displayed significant higher scores for three independent genomic scar signatures [<bibcit rid="bib41" title="bibcit" href="#" contenteditable="false" id="link_d3e1803129" sno="41">41</bibcit>] — loss of heterozygosity (LOH), large-scale transition (LST) and telomeric allelic imbalance (TAI) (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1806130" sno="7">7</figcit>B), suggesting an increased burden of chromosomal instability with low PRRX1 expression. Furthermore, STAD tumor samples exhibited significantly higher expression levels of <i>PRRX1</i> compared to non-tumor tissues (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1813131" sno="7">7</figcit>C). High <i>PRRX1</i> expression was associated with poorer overall survival (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1819132" sno="7">7</figcit>D) and correlated with a worse prognosis in STAD patients undergoing radiotherapy (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1822133" sno="7">7</figcit>E).</p><fig id="fig7" prefix="Figure" suffix="." sno="7" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="7" type="arabic" sub-type="">PRRX1 loss or mutation causes genome instability and NHEJ defect. <b>(A, B)</b> The genomic instability signatures [the weighted genomic integrity index (wGII) <b>(A)</b>] and the genomic scar signatures (LOH, LST and TAI) <b>(B)</b> were analyzed using the TCGA stomach adenocarcinoma (STAD) cohort. The data were grouped based on <i>PRRX1</i> expression levels using the median cutoff. The outline of each box represents the 25<sup>th</sup> and 75<sup>th</sup> percentiles, with solid lines indicating median values. The whiskers extend to the most extreme data points within 1.5 × the interquartile range. Statistical significance was determined using a two-tailed Mann–Whitney Wilcoxon test. LOH: loss of heterozygosity; LST, large-scale transition; TAI, telomeric allelic imbalance. <b>(C)</b> Expression difference of <i>PRRX1</i> in STAD samples. The data were based on the TCGA database and retrieved <i>via</i> the GEPIA2 website. <b>(D, E)</b> Kaplan-Meier survival curves for overall survival of STAD patients with high [top 30 <b>(D)</b> or 50 <b>(E)</b> percentile] or low [bottom 70 <b>(D)</b> or 50 <b>(E)</b> percentile] <i>PRRX1</i> expression. Data were based on the TCGA database. The hazard ratio (HR) and log-rank p value were indicated in each panel. <b>(F)</b> The diagram illustrating PRRX1 mutations identified in various tumors. Data were retrieved from the ICGC database. Numbers represent case frequencies. <b>(G)</b> MBP pull-down assays using recombinant MBP-PA and MBP-PA<sup>R145Q</sup> to co-purify His-Ku70/80. Co-purified products were immunoblotted with indicated antibodies. <b>(H)</b> DNA pull-down of dsDNA with recombinant MBP-PA and MBP-PA<sup>R145Q</sup>. Co-purified products were immunoblotted with an anti-MBP antibody. <b>(I)</b> EJ5-GFP NHEJ reporter assays of U2OS cells overexpressing mCherry or mCherry-PA<sup>R145Q</sup> (<i>n </i>= 5 biologically replicates). Statistical analysis was performed using two-tailed unpaired <i>t</i>-test. <b>(J)</b> Left: survival analyses of Hs746T STAD cells with indicated treatment. Statistical analysis was performed using two-way ANOVA. Right: cell lysates were immunoblotted with indicated antibodies.</ti><img src="gkaf2001_f7.jpg" title="Figure"></img></fig><p t="i" title="Paragraph Indented">By analyzing the International Cancer Genome Consortium (ICGC) database, a series of mutation sites on <i>PRRX1</i> were identified in patients with various cancers (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1916134" sno="7">7</figcit>F). Among them, properties of PRRX1<sup>R145Q</sup>, found in cancer samples including STAD, breast cancer and colon cancer, were inspected. Strikingly, PRRX1<sup>R145Q</sup> could bind to Ku70/80 but not dsDNA (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1925135" sno="7">7</figcit>G, H). Consistently, PRRX1<sup>R145Q</sup> was unable to enhance NHEJ repair (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1932136" sno="7">7</figcit>I), implying that tumors harboring PRRX1<sup>R145Q</sup> might be more sensitivity to DNA damaging agents. We then studied how PRRX1 affects the response to IR in PRRX1 abundant Hs746 STAD cells, a preclinical model representing the “mesenchymal-like” or “genome stability” subtype of STAD [<bibcit rid="bib58" title="bibcit" href="#" contenteditable="false" id="link_d3e1938137" sno="58">58</bibcit>, <bibcit rid="bib59" title="bibcit" href="#" contenteditable="false" id="link_d3e1941138" sno="59">59</bibcit>, <bibcit rid="bib60" title="bibcit" href="#" contenteditable="false" id="link_d3e1944139" sno="60">60</bibcit>]. Loss of PRRX1 caused hypersensitivity to irradiation, which was fully rescued by overexpressing wild-type PRRX1 but only partially rescued by the PRRX1A<sup>R145Q</sup> mutant (Fig. <figcit rid="fig7" title="figcit" href="#" contenteditable="false" id="link_d3e1951140" sno="7">7</figcit>J). Together, given its role in facilitating NHEJ, PRRX1 may serve as a potential target to enhance radiotherapy effectiveness for specific subtypes of STAD.</p></sect2><sect2 id="sec3-10"><ti title="Heading 2">The peptide disrupting PRRX1 oligomerization blocks NHEJ</ti><p t="fl" title="Paragraph No Indent">We finally sought to modulate NHEJ efficiency by disrupting the oligomerization of PRRX1. The competing nine-amino acid peptide, targeting the N-terminal helix α1 of PRRX1’s homeodomain, was synthesized and placed at the carboxyl end of the biotinylated TAT peptide to promote nuclear entry. A five-amino acid mutated peptide was also synthesized to serve as the control (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1959141" sno="8">8</figcit>A). The MBP pull-down assay revealed that the competing peptide, but not the mutated peptide greatly compromised the self-binding of MBP- and His-PRRX1 (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1962142" sno="8">8</figcit>B), while both peptides exhibiting no effect on the interaction between MBP-PRRX1 and Ku70/80 (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1965143" sno="8">8</figcit>C). Importantly, the competing peptide reduced NHEJ efficiency in both mock and PRRX1-overexpressing U2OS cells (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1968144" sno="8">8</figcit>D), and the number of γH2AX foci was significantly higher in cells treated with competing peptide compared to those treated with the mutant peptide (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1971145" sno="8">8</figcit>E, F). Additionally, the presence of the competing peptide attenuated the phosphorylation of DNA-PKcs at serine 2056 in Hs746T cells following IR treatment (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1975146" sno="8">8</figcit>G). Consistently, the competing rather than the mutant peptide, significantly undermined the survival of irradiated Hs746T cells (Fig. <figcit rid="fig8" title="figcit" href="#" contenteditable="false" id="link_d3e1978147" sno="8">8</figcit>H). Thus, disrupting the oligomerization of PRRX1 may represent a potential therapeutic strategy for treating STAD.</p><fig id="fig8" prefix="Figure" suffix="." sno="8" type="arabic" sub-type=""><ti title="Figure Caption" prefix="Figure" suffix="." sno="8" type="arabic" sub-type="">The peptide disrupting PRRX1 oligomerization blocks NHEJ. <b>(A)</b> A diagram depicting the peptide design (competing and mutated peptides) for perturbing PRRX1 oligomerization. The N-terminal TAT peptide was used to facilitate cell entry. <b>(B, C)</b> MBP pull-down assays using recombinant MBP-PA to co-purify His-PA <b>(B)</b> and His-Ku70/80 <b>(C)</b> with the presence of indicated peptides. Co-purified products were immunoblotted with indicated antibodies. The indicated proportions (peptides: PRRX1) represent the ratio of molar concentration. <b>(D)</b> EJ5-GFP NHEJ reporter assays of U2OS cells overexpressing EV or PA with the presence of indicated peptides. <i>n </i>= 5 biologically replicates. Statistical analysis was performed using two-way ANOVA. <b>(E)</b> Hs746T cells were irradiated and treated with 40 μM indicated peptides. Immunofluorescence images (red, γH2AX; blue, DAPI; green, biotinylated peptides). UT, untreated. Scale bars, 10 μm. <b>(F)</b> Quantification of γH2AX foci in <b>(E)</b>. Data are mean ± 95% CI. Each point represents a cell; 60 cells quantified in each group were obtained from two independent experiments. Statistical analysis was performed using two-tailed unpaired <i>t-</i>tests. <b>(G)</b> Hs746T cells were treated with 40 μM peptides and harvested at indicated time post IR. Cell lysates were immunoblotted with indicated antibodies. <b>(H)</b> Survival analysis of Hs746T cell with indicated treatment. Statistical analysis was performed using two-way ANOVA.</ti><img src="gkaf2001_f8.jpg" title="Figure"></img></fig></sect2></sect1><sect1 id="sec4" sec-type="discussion"><ti title="Heading 1">Discussion</ti><p t="fl" title="Paragraph No Indent">The initiation of NHEJ requires the attachment of Ku70/80 to the DSB ends, enabling the formation and activation of the DNA-PK holoenzyme. However, many questions remain regarding how Ku70/80 is attached and stabilized at broken DNA ends. In current study, we unveiled a novel role for PRRX1, conventionally recognized as a HD transcription factor, in promoting the accumulation of Ku70/80-DNA-PKcs on DSBs. PRRX1 oligomerizes to enable its simultaneous interactions with both dsDNA and the SAP domain of Ku70, thereby enhancing Ku anchoring at DSBs to stabilize DNA-PK for efficient NHEJ repair (Graphical Abstract). The study advances our understandings of the molecular mechanisms underlying NHEJ and offers novel insights into cancer therapeutics.</p><sect2 id="sec4-1"><ti title="Heading 2">Oligomerized PRRX1 modulates the dynamics of the DNA-PK complex at DSB sites</ti><p t="fl" title="Paragraph No Indent">The ring-shaped Ku70/80 binds dsDNA by contacting a few DNA backbone phosphates, allowing ATP-independent sliding along DNA. Structural studies show the SAP domain in Ku70/80, a flexible DNA aperture component, facilitates initial Ku-DNA contact [<bibcit rid="bib61" title="bibcit" href="#" contenteditable="false" id="link_d3e2036148" sno="61">61</bibcit><query><button type="button" title="AU: Please note that the reference citations in the  text have been reordered to be in sequential order. Check and correct where necessary directly in the references." contenteditable="false" query-type="open" roleid="12" conversation-uid="15" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">15</span></button></query>], acting as a “linker” connecting NHEJ machinery with co-factors. The Ku80 C-terminal stabilizes the DNA-PK complex but is not essential for its formation. The Ku70 SAP domain is critical for Ku70/80 association with dsDNA <i>in vivo</i> [<bibcit rid="bib19" title="bibcit" href="#" contenteditable="false" id="link_d3e2043149" sno="19">19</bibcit>,<bibcit rid="bib20" title="bibcit" href="#" contenteditable="false" id="link_d3e2046150" sno="20">20</bibcit>], but its role in localizing Ku70/80 to damaged DNA ends remains unresolved. Recent findings suggest that the Ku70 SAP domain limits Ku's lateral movement along DNA and is essential for repairing exogenous DSBs [<bibcit rid="bib62" title="bibcit" href="#" contenteditable="false" id="link_d3e2049151" sno="62">62</bibcit>,<bibcit rid="bib63" title="bibcit" href="#" contenteditable="false" id="link_d3e2053152" sno="63">63</bibcit>].</p><p t="i" title="Paragraph Indented">Several factors regulate NHEJ by interacting with Ku heterodimers. For instance, ZNF384 acts as an adapter binding to DNA and Ku70 in a PARP1-dependent manner, promoting Ku70/80 accumulation at DSBs [<bibcit rid="bib28" title="bibcit" href="#" contenteditable="false" id="link_d3e2058153" sno="28">28</bibcit>]. VAV2 facilitates Ku heterodimer formation by binding Ku70 and Ku80, enhancing NHEJ [<bibcit rid="bib64" title="bibcit" href="#" contenteditable="false" id="link_d3e2061154" sno="64">64</bibcit>]. Methylation of Ku70 by SMYD2 promotes DNA-PK complex assembly [<bibcit rid="bib29" title="bibcit" href="#" contenteditable="false" id="link_d3e2064155" sno="29">29</bibcit>]. Conversely, FOXL2 and LRRC31 inhibit Ku70/80 heterodimer or DNA-PK complex formation, weakening NHEJ repair [<bibcit rid="bib37" title="bibcit" href="#" contenteditable="false" id="link_d3e2067156" sno="37">37</bibcit>,<bibcit rid="bib65" title="bibcit" href="#" contenteditable="false" id="link_d3e2070157" sno="65">65</bibcit>]. Interestingly, the Ku70 SAP domain associates with several HD proteins<i>.</i> Schild-Poulter <i>et al.</i> identified Ku70 interactions with HD proteins, including HOXC4, HOXD4, and OCT2, in yeast [<bibcit rid="bib66" title="bibcit" href="#" contenteditable="false" id="link_d3e2080158" sno="66">66</bibcit>], though their role in DNA damage was unclear. Later, Rubi <i>et al.</i> found elevated HOXB7 expression in human breast epithelial cells enhanced resistance to DNA damage, suggesting HD proteins might assist DNA repair as Ku70 partners [<bibcit rid="bib67" title="bibcit" href="#" contenteditable="false" id="link_d3e2086159" sno="67">67</bibcit>]. Mechanistic studies confirmed that HOXB7 binds to Ku70, Ku80, and DNA-PKcs <i>via</i> its HD domain, linking DNA damage resistance to these interactions. CDX2, another HD protein, binds Ku70 through its HD domain in colorectal cancer cells but inhibits DNA-PK activity [<bibcit rid="bib68" title="bibcit" href="#" contenteditable="false" id="link_d3e2093160" sno="68">68</bibcit>]. While Ku70 binding appears to be a common feature of HD proteins, its precise role in NHEJ repair and the underlying mechanisms remain insufficiently explored.</p><p t="i" title="Paragraph Indented">In current study, we discovered that HD protein PRRX1 binds to the SAP domain of Ku70. Importantly, depletion of PRRX1 markedly reduced the enrichment of Ku70/80 on the chromatin and compromised NHEJ, whereas the opposite effect was observed upon PRRX1 overexpression. In particular, PRRX1, despite being relatively small, simultaneously interacts with the SAP domain of Ku70 and dsDNA through its NRR motif within the homeodomain. PRRX1 achieves this by forming oligomers <i>via</i> its N-terminal helix α1 (107–115 aa) in the HD domain. Of note, the motif essential for PRRX1 oligomerization is unique to PRRX1 and not found in other HD proteins, making it a potential target for improving cancer treatment. Indeed, the competing peptide that disrupts PRRX1 oligomerization blocked NHEJ and hampered the survival of irradiated STAD cells. In addition, we also revealed that PRRX1-specific sequences at both N-terminal and C-termnial parts are involved in its association with Ku70 and dsDNA, as well as oligomerization.</p></sect2><sect2 id="sec4-2"><ti title="Heading 2">PRRX1 senses and accumulates at DNA damage sites</ti><p t="fl" title="Paragraph No Indent">LMI studies revealed that both endogenous and exogenous PRRX1 rapidly accumulate at DNA damage sites. Intriguingly, this accumulation occurs irrespective of known DNA damage sensors, including PARP1, Ku, and the MRN complex, as well as upstream kinases such as ATM and DNA-PKcs. Instead, PRRX1 directly binds to various forms of dsDNA with random sequences but not ssDNA <i>in vitro</i>. Moreover, PRRX1 was found to be associated with chromatin along with Ku70/80 in untreated, irradiated, and ETP treated cells. Further investigations are needed to determine whether PRRX1 exhibits a preference for specific regions or sequences in terms of chromatin and DSB association.</p><p t="i" title="Paragraph Indented">The two isoforms of PRRX1 have different C-terminal ends, which are seemingly not required for its oligomerization or DNA or Ku70 binding. Moreover, both exogenous PRRX1A and PRRX1B exhibited the same kinetics in the recruitment to DSBs. However, we have revealed a few discrepancies of the two isoforms. First, DNA pull-down assays demonstrated that the shorter PRRX1A had a stronger affinity for dsDNA. We speculate that potential co-factors or post-translational modifications of PRRX1 in the cellular context might compensate for the difference in their dsDNA affinity. Second, the sucrose gradient separation assay indicated that the two isoforms were enriched in adjacent and overlapping compartments. Third, the oligomerization efficiency of PRRX1A is higher than PRRX1B. Fourth, the NHEJ efficiency in cells overexpressing PRRX1A was around 10% higher than those overexpressing PRRX1B. Further investigation is needed to determine whether the two isoforms are differentially utilized in specific cellular or stress contexts. Additionally, the possibility that PRRX1A and PRRX1B function as heterodimers should be explored.</p></sect2><sect2 id="sec4-3"><ti title="Heading 2">PRRX1 is associated with defective NHEJ repair in certain cancer types</ti><p t="fl" title="Paragraph No Indent">PRRX1, traditionally recognized as a transcription factor, plays essential roles in specification of mesodermal and neural crest lineages, as well as in the tumorigenesis and metastasis of cancer cells. We have previously demonstrated that the NRR motif is crucial for PRRX1’s transcriptional function [<bibcit rid="bib46" title="bibcit" href="#" contenteditable="false" id="link_d3e2116161" sno="46">46</bibcit>]. Interestingly, PRRX1 could transcriptionally maintain the expressions of DDR genes including <i>ATM</i>, <i>ATR</i>, <i>BRCA1</i>, <i>PRKDC</i>, and <i>XRCC1</i>, in PANC1 pancreatic cancer cells [<bibcit rid="bib34" title="bibcit" href="#" contenteditable="false" id="link_d3e2135162" sno="34">34</bibcit>]. Here we unveiled the transcription-independent role of PRRX1 in promoting NHEJ. As anticipated, the conserved NRR motif (144–146 aa) within the HD domain is required for PRRX1’s DNA association, and other domains could facilitate the binding, likely by maintaining the proper conformation.</p><p t="i" title="Paragraph Indented">We have meticulously examined the impact of NRR mutations, including the R145Q mutant, identified in various cancers such as STAD, on Ku- and dsDNA-binding, as well as oligomerization. These mutated PRRX1 losses the ability to associate with either Ku70 or dsDNA, ultimately leading to the defect of facilitating NHEJ. In STAD, low expression levels of <i>PRRX1</i> associate with genomic instability, while high expression levels of PRRX1 correlate with poor prognosis and IR resistance. It remains to be investigated whether PRRX1 has a transcription-independent role in regulating cancer microenvironment, such as cancer-associated fibroblasts [<bibcit rid="bib32" title="bibcit" href="#" contenteditable="false" id="link_d3e2143163" sno="32">32</bibcit>], and how PRRX1-mediated regulation of NHEJ efficiency could influence responses to combination therapies, particularly those involving immune checkpoint inhibitors.</p></sect2></sect1><sect1 sec-type="ack"><ti title="Acknowledgement Heading">Acknowledgements</ti><p t="fl" title="Paragraph No Indent">We thank Drs Pingkun Zhou, Dongyi Xu, Yanhui Xu, Jun Huang, Shu Li and Junjie Zhang for providing cell lines, plasmids, and reagents. We thank the Core Facility and the Animal Facility of Medical Research Institute of Wuhan University for technical support. We thank all Zhou lab members for critical reading of the manuscript<query><button type="button" title="AU: Please ensure all 'conflicts of interest' (or 'disclosures') have been included for you and your co-authors, and that this section is correct. Edit the text directly if changes are required." contenteditable="false" query-type="open" roleid="12" conversation-uid="16" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">16</span></button></query><query><button type="button" title="AU: Please check that funding is recorded in a separate funding section, if applicable. Use the full official names of any funding bodies and include any grant numbers. Insert any changes to the funding section directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="17" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">17</span></button></query>.</p></sect1><sect1 id="sec5" sec-type="author-contrib"><ti title="Heading 1">Author contributions</ti><p t="fl" title="Paragraph No Indent">Y.Z. conceived the study. Y.Z., Y.W. and F.S. designed the experiments. Y.W., F.S., J.L., W.W., F.W. and J.G. performed experiments and analyses. C.Z. conducted bioinformatics analyses. Y.L. and F.W. helped with plasmid construction. Y.Z., Y.W and F.S. wrote the paper. H.Z., X.C. and Q.C. helped with experimental design and manuscript preparation. Y.Z., Y.L. and F.W provided funding and supervised the project. All authors participated in scientific discussions.</p></sect1><sect1 id="sec6" sec-type="supplementary-data"><ti title="Heading 1">Supplementary data</ti><p t="fl" title="Paragraph No Indent"><url title="URL" type="uri" href="https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/gkaf2001#supplementary-data">Supplementary Data</url> are available at NAR online.</p></sect1><sect1 id="sec7" sec-type="conflict"><ti title="Heading 1">Conflict of interest statement</ti><p t="fl" title="Paragraph No Indent">Noadne declared.</p></sect1><sect1 id="sec8" sec-type="funding"><ti title="Heading 1">Funding</ti><p t="fl" title="Paragraph No Indent">This work was supported by grants from <hi type="funding-source">National Key R&amp;D Program of China</hi> (<hi type="award-id">2022YFA0806603</hi>), <hi type="funding-source">National Natural Science Foundation of China</hi> (<hi type="award-id">32470776</hi>, <hi type="award-id">32270876</hi>, and <hi type="award-id">32300660</hi>), and the <hi type="funding-source">Fundamental Research Funds for the Central Universities</hi> (<hi type="award-id">2042022dx0003</hi> and <hi type="award-id">2042023kf0234</hi>).</p></sect1><sect1 id="sec9" sec-type="data-availability"><ti title="Heading 1">Data availability</ti><p t="fl" title="Paragraph No Indent">The RNA-seq data of MEFs have been deposited in the GEO database (<url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_005012) with accession number GSE265857 (Access link: <url title="URL" type="uri" href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE265857">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE265857</url>; Password: ehkvascqdnmlbgh). The MS data have been deposited to the ProteomeXchange Consortium (<query><button type="button" title="AU: Please note that the URL 'http://proteomecentral' is not valid/accessible. Please check and include a working URL directly in the text." contenteditable="false" query-type="open" roleid="12" conversation-uid="18" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">18</span></button></query><url title="URL" type="uri" href="http://proteomecentral">http://proteomecentral</url>. proteomexchange.org; <url title="URL" type="uri" href="https://scicrunch.org/resolver/https://scicrunch.org/resolver/RRID:">RRID:</url> SCR_004055) via the iProX repository [<bibcit rid="bib69" title="bibcit" href="#" contenteditable="false" id="link_d3e2223164" sno="69">69</bibcit>] with the dataset identifier PXD051766 (Access link: <url title="URL" type="uri" href="https://www.iprox.cn/page/PSV023.html;?url=1714117094993dGyS">https://www.iprox.cn/page/PSV023.html;?url=1714117094993dGyS</url>; Password: a509). All data are publicly available from the date of publication. Any additional information required to reanalyze the data in this paper is available from the authors upon rational request. The graphical abstract was created in BioRender. Wang, Y. (2025) <url title="URL" type="uri" href="https://BioRender.com/n48o611">https://BioRender.com/n48o611</url><query><button type="button" title="AU: We have received the following files for publication as supplementary material. &amp;lsqb;Filename&amp;rsqb; These will be published in the format provided, without edits. If any files need to be removed from this list, specify by responding to this query, stating the filename. If any files need to be added, upload them directly or email them with your proof corrections. If any files need to be updated, upload them directly or email them, without altering the filename. We will seek editor approval for any changes to supplementary material, which may delay publication of your article." contenteditable="false" query-type="open" roleid="12" conversation-uid="19" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">19</span></button></query></p></sect1></bdy><bm><ref type="arabic" sno="1" suffix="." id="ref1"><ti title="Bibliography Heading">References</ti><bib type="arabic" id="bib1" sno="1" suffix="."><jcit><au><s title="Surname">Krenning</s> <f title="First name">L</f></au>, <au><s title="Surname">van den Berg</s><f title="First name">J</f></au>, <au><s title="Surname">Medema</s><f title="First name">RH</f></au>. <at title="Article Title">Life or death after a break: what determines the choice?</at> <pt title="Periodical Title">Mol Cell</pt> <yr title="Year">2019</yr>;<v title="Volume">76</v>:<pages title="Pages">346–58</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.molcel.2019.08.023">https://doi.org/10.1016/j.molcel.2019.08.023</url> </jcit></bib><bib type="arabic" id="bib2" sno="2" suffix="."><jcit><au><s title="Surname">Petr</s><f title="First name">MA</f></au>, <au><s title="Surname">Tulika</s><f title="First name">T</f></au>, <au><s title="Surname">Carmona-Marin</s><f title="First name">LM</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Protecting the aging genome</at>. <pt title="Periodical Title">Trends Cell Biol</pt> <yr title="Year">2020</yr>;<v title="Volume">30</v>:<pages title="Pages">117–32</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.tcb.2019.12.001">https://doi.org/10.1016/j.tcb.2019.12.001</url> </jcit></bib><bib type="arabic" id="bib3" sno="3" suffix="."><jcit><au><s title="Surname">Schumacher</s><f title="First name">B</f></au>, <au><s title="Surname">Pothof</s><f title="First name">J</f></au>, <au><s title="Surname">Vijg</s><f title="First name">J</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The central role of DNA damage in the ageing process</at>. <pt title="Periodical Title">Nature</pt> <yr title="Year">2021</yr>;<v title="Volume">592</v>:<pages title="Pages">695–703</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41586-021-03307-7">https://doi.org/10.1038/s41586-021-03307-7</url> </jcit></bib><bib type="arabic" id="bib4" sno="4" suffix="."><jcit><au><s title="Surname">Chapman</s><f title="First name">JR</f></au>, <au><s title="Surname">Taylor</s><f title="First name">MR</f></au>, <au><s title="Surname">Boulton</s><f title="First name">SJ</f></au>. <at title="Article Title">Playing the end game: DNA double-strand break repair pathway choice</at>. <pt title="Periodical Title">Mol Cell</pt> <yr title="Year">2012</yr>;<v title="Volume">47</v>:<pages title="Pages">497–510</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.molcel.2012.07.029">https://doi.org/10.1016/j.molcel.2012.07.029</url> </jcit></bib><bib type="arabic" id="bib5" sno="5" suffix="."><jcit><au><s title="Surname">Ceccaldi</s><f title="First name">R</f></au>, <au><s title="Surname">Rondinelli</s><f title="First name">B</f></au>, <au><s title="Surname">D’Andrea</s><f title="First name">AD</f></au>. <at title="Article Title">Repair pathway choices and consequences at the double-strand break</at>. <pt title="Periodical Title">Trends Cell Biol</pt> <yr title="Year">2016</yr>;<v title="Volume">26</v>:<pages title="Pages">52–64</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.tcb.2015.07.009">https://doi.org/10.1016/j.tcb.2015.07.009</url> </jcit></bib><bib type="arabic" id="bib6" sno="6" suffix="."><jcit><au><s title="Surname">Scully</s><f title="First name">R</f></au>, <au><s title="Surname">Panday</s><f title="First name">A</f></au>, <au><s title="Surname">Elango</s><f title="First name">R</f></au> <etal title="etal">et al.</etal> <at title="Article Title">DNA double-strand break repair-pathway choice in somatic mammalian cells</at>. <pt title="Periodical Title">Nat Rev Mol Cell Biol</pt> <yr title="Year">2019</yr>;<v title="Volume">20</v>:<pages title="Pages">698–714</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41580-019-0152-0">https://doi.org/10.1038/s41580-019-0152-0</url> </jcit></bib><bib type="arabic" id="bib7" sno="7" suffix="."><jcit><au><s title="Surname">Symington</s><f title="First name">LS</f></au>, <au><s title="Surname">Gautier</s><f title="First name">J</f></au>. <at title="Article Title">Double-strand break end resection and repair pathway choice</at>. <pt title="Periodical Title">Annu. Rev. Genet.</pt> <yr title="Year">2011</yr>;<v title="Volume">45</v>:<pages title="Pages">247–71</pages>. <url title="URL" type="uri" href="https://doi.org/10.1146/annurev-genet-110410-132435">https://doi.org/10.1146/annurev-genet-110410-132435</url> </jcit></bib><bib type="arabic" id="bib8" sno="8" suffix="."><jcit><au><s title="Surname">Her</s><f title="First name">J</f></au>, <au><s title="Surname">Bunting</s><f title="First name">SF</f></au>. <at title="Article Title">How cells ensure correct repair of DNA double-strand breaks</at>. <pt title="Periodical Title">J Biol Chem</pt> <yr title="Year">2018</yr>;<v title="Volume">293</v>:<pages title="Pages">10502–11</pages>. <url title="URL" type="uri" href="https://doi.org/10.1074/jbc.TM118.000371">https://doi.org/10.1074/jbc.TM118.000371</url> </jcit></bib><bib type="arabic" id="bib9" sno="9" suffix="."><jcit><au><s title="Surname">Chang</s><f title="First name">HHY</f></au>, <au><s title="Surname">Pannunzio</s><f title="First name">NR</f></au>, <au><s title="Surname">Adachi</s><f title="First name">N</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Non-homologous DNA end joining and alternative pathways to double-strand break repair</at>. <pt title="Periodical Title">Nat Rev Mol Cell Biol</pt> <yr title="Year">2017</yr>;<v title="Volume">18</v>:<pages title="Pages">495–506</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nrm.2017.48">https://doi.org/10.1038/nrm.2017.48</url> </jcit></bib><bib type="arabic" id="bib10" sno="10" suffix="."><jcit><au><s title="Surname">Zhao</s><f title="First name">B</f></au>, <au><s title="Surname">Rothenberg</s><f title="First name">E</f></au>, <au><s title="Surname">Ramsden</s><f title="First name">DA</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The molecular basis and disease relevance of non-homologous DNA end joining</at>. <pt title="Periodical Title">Nat Rev Mol Cell Biol</pt> <yr title="Year">2020</yr>;<v title="Volume">21</v>:<pages title="Pages">765–81</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41580-020-00297-8">https://doi.org/10.1038/s41580-020-00297-8</url> </jcit></bib><bib type="arabic" id="bib11" sno="11" suffix="."><jcit><au><s title="Surname">Liu</s><f title="First name">C</f></au>, <au><s title="Surname">Srihari</s><f title="First name">S</f></au>, <au><s title="Surname">Cao</s><f title="First name">KA</f></au> <etal title="etal">et al.</etal> <at title="Article Title">A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">2014</yr>;<v title="Volume">42</v>:<pages title="Pages">6106–27</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gku284">https://doi.org/10.1093/nar/gku284</url> </jcit></bib><bib type="arabic" id="bib12" sno="12" suffix="."><jcit><au><s title="Surname">Samadder</s><f title="First name">P</f></au>, <au><s title="Surname">Aithal</s><f title="First name">R</f></au>, <au><s title="Surname">Belan</s><f title="First name">O</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Cancer TARGETases: DSB repair as a pharmacological target</at>. <pt title="Periodical Title">Pharmacol Ther</pt> <yr title="Year">2016</yr>;<v title="Volume">161</v>:<pages title="Pages">111–31</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.pharmthera.2016.02.007">https://doi.org/10.1016/j.pharmthera.2016.02.007</url> </jcit></bib><bib type="arabic" id="bib13" sno="13" suffix="."><jcit><au><s title="Surname">Lu</s><f title="First name">H</f></au>, <au><s title="Surname">Saha</s><f title="First name">J</f></au>, <au><s title="Surname">Beckmann</s><f title="First name">PJ</f></au> <etal title="etal">et al.</etal> <at title="Article Title">DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">2019</yr>;<v title="Volume">47</v>:<pages title="Pages">9467–79</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkz694">https://doi.org/10.1093/nar/gkz694</url> </jcit></bib><bib type="arabic" id="bib14" sno="14" suffix="."><jcit><au><s title="Surname">Menolfi</s><f title="First name">D</f></au>, <au><s title="Surname">Zha</s><f title="First name">S</f></au>. <at title="Article Title">DNA-PKcs kinase activity orchestrates both end-processing and end-ligation</at>. <pt title="Periodical Title">Trends Cell Biol</pt> <yr title="Year">2022</yr>;<v title="Volume">32</v>:<pages title="Pages">91–3</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.tcb.2021.12.002">https://doi.org/10.1016/j.tcb.2021.12.002</url> </jcit></bib><bib type="arabic" id="bib15" sno="15" suffix="."><jcit><au><s title="Surname">Walker</s><f title="First name">JR</f></au>, <au><s title="Surname">Corpina</s><f title="First name">RA</f></au>, <au><s title="Surname">Goldberg</s><f title="First name">J</f></au>. <at title="Article Title">Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair</at>. <pt title="Periodical Title">Nature</pt> <yr title="Year">2001</yr>;<v title="Volume">412</v>:<pages title="Pages">607–14</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/35088000">https://doi.org/10.1038/35088000</url> </jcit></bib><bib type="arabic" id="bib16" sno="16" suffix="."><jcit><au><s title="Surname">Yin</s><f title="First name">X</f></au>, <au><s title="Surname">Liu</s><f title="First name">M</f></au>, <au><s title="Surname">Tian</s><f title="First name">Y</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Cryo-EM structure of human DNA-PK holoenzyme</at>. <pt title="Periodical Title">Cell Res</pt> <yr title="Year">2017</yr>;<v title="Volume">27</v>:<pages title="Pages">1341–50</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/cr.2017.110">https://doi.org/10.1038/cr.2017.110</url> </jcit></bib><bib type="arabic" id="bib17" sno="17" suffix="."><jcit><au><s title="Surname">Radhakrishnan</s><f title="First name">SK</f></au>, <au><s title="Surname">Lees-Miller</s><f title="First name">SP</f></au>. <at title="Article Title">DNA requirements for interaction of the C-terminal region of Ku80 with the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)</at>. <pt title="Periodical Title">DNA Repair (Amst)</pt> <yr title="Year">2017</yr>;<v title="Volume">57</v>:<pages title="Pages">17–28</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.dnarep.2017.06.001">https://doi.org/10.1016/j.dnarep.2017.06.001</url> </jcit></bib><bib type="arabic" id="bib18" sno="18" suffix="."><jcit><au><s title="Surname">Sibanda</s><f title="First name">BL</f></au>, <au><s title="Surname">Chirgadze</s><f title="First name">DY</f></au>, <au><s title="Surname">Ascher</s><f title="First name">DB</f></au> <etal title="etal">et al.</etal> <at title="Article Title">DNA-PKcs structure suggests an allosteric mechanism modulating DNA double-strand break repair</at>. <pt title="Periodical Title">Science</pt> <yr title="Year">2017</yr>;<v title="Volume">355</v>:<pages title="Pages">520–4</pages>. <url title="URL" type="uri" href="https://doi.org/10.1126/science.aak9654">https://doi.org/10.1126/science.aak9654</url> </jcit></bib><bib type="arabic" id="bib19" sno="19" suffix="."><jcit><au><s title="Surname">Anisenko</s><f title="First name">AN</f></au>, <au><s title="Surname">Knyazhanskaya</s><f title="First name">ES</f></au>, <au><s title="Surname">Zatsepin</s><f title="First name">TS</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Human Ku70 protein binds hairpin RNA and double stranded DNA through two different sites</at>. <pt title="Periodical Title">Biochimie</pt> <yr title="Year">2017</yr>;<v title="Volume">132</v>:<pages title="Pages">85–93</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.biochi.2016.11.001">https://doi.org/10.1016/j.biochi.2016.11.001</url> </jcit></bib><bib type="arabic" id="bib20" sno="20" suffix="."><jcit><au><s title="Surname">Inagawa</s><f title="First name">T</f></au>, <au><s title="Surname">Wennink</s><f title="First name">T</f></au>, <au><s title="Surname">Lebbink</s><f title="First name">JHG</f></au> <etal title="etal">et al.</etal> <at title="Article Title">C-terminal extensions of Ku70 and Ku80 differentially influence DNA end binding properties</at>. <pt title="Periodical Title">Int J Mol Sci</pt> <yr title="Year">2020</yr>;<v title="Volume">21</v>. <url title="URL" type="uri" href="https://doi.org/10.3390/ijms21186725">https://doi.org/10.3390/ijms21186725</url> <query><button type="button" title="AU: Pages is missing in this reference &amp;lsqb;20&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="20" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">20</span></button></query></jcit></bib><bib type="arabic" id="bib21" sno="21" suffix="."><jcit><au><s title="Surname">Fulnecek</s><f title="First name">J</f></au>, <au><s title="Surname">Klimentova</s><f title="First name">E</f></au>, <au><s title="Surname">Cairo</s><f title="First name">A</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The SAP domain of Ku facilitates its efficient loading onto DNA ends</at>. <pt title="Periodical Title">Nucleic Acids Res </pt><yr title="Year">2023</yr>; <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkad850">https://doi.org/10.1093/nar/gkad850</url> <query><button type="button" title="AU: Volume and Pages are missing in this reference &amp;lsqb;21&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="21" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">21</span></button></query></jcit></bib><bib type="arabic" id="bib22" sno="22" suffix="."><jcit><au><s title="Surname">Bao</s><f title="First name">K</f></au>, <au><s title="Surname">Ma</s><f title="First name">Y</f></au>, <au><s title="Surname">Li</s><f title="First name">Y</f></au> <etal title="etal">et al.</etal> <at title="Article Title">A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis</at>. <pt title="Periodical Title">Mol Cell</pt> <yr title="Year">2024</yr>;<v title="Volume">84</v>:<pages title="Pages">1206–1223.e15 e1215</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.molcel.2024.02.002">https://doi.org/10.1016/j.molcel.2024.02.002</url> </jcit></bib><bib type="arabic" id="bib23" sno="23" suffix="."><jcit><au><s title="Surname">Chen</s><f title="First name">R</f></au>, <au><s title="Surname">Zhao</s><f title="First name">M-J</f></au>, <au><s title="Surname">Li</s><f title="First name">Y-M</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Di- and tri-methylation of histone H3K36 play distinct roles in DNA double-strand break repair</at>. <pt title="Periodical Title">SCIENCE CHINA Life Sciences</pt><query><button type="button" title="AU: Volume, Year and Pages are missing in this reference &amp;lsqb;23&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="22" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">22</span></button></query></jcit></bib><bib type="arabic" id="bib24" sno="24" suffix="."><jcit><au><s title="Surname">Hung</s><f title="First name">PJ</f></au>, <au><s title="Surname">Johnson</s><f title="First name">B</f></au>, <au><s title="Surname">Chen</s><f title="First name">BR</f></au> <etal title="etal">et al.</etal> <at title="Article Title">MRI is a DNA damage response adaptor during classical non-homologous end joining</at>. <pt title="Periodical Title">Mol Cell</pt> <yr title="Year">2018</yr>;<v title="Volume">71</v>:<pages title="Pages">332–342.e8 e338</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.molcel.2018.06.018">https://doi.org/10.1016/j.molcel.2018.06.018</url> </jcit></bib><bib type="arabic" id="bib25" sno="25" suffix="."><jcit><au><s title="Surname">Arnoult</s><f title="First name">N</f></au>, <au><s title="Surname">Correia</s><f title="First name">A</f></au>, <au><s title="Surname">Ma</s><f title="First name">J</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN</at>. <pt title="Periodical Title">Nature</pt> <yr title="Year">2017</yr>;<v title="Volume">549</v>:<pages title="Pages">548–52</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nature24023">https://doi.org/10.1038/nature24023</url> </jcit></bib><bib type="arabic" id="bib26" sno="26" suffix="."><jcit><au><s title="Surname">Liu</s><f title="First name">XS</f></au>, <au><s title="Surname">Chandramouly</s><f title="First name">G</f></au>, <au><s title="Surname">Rass</s><f title="First name">E</f></au> <etal title="etal">et al.</etal> <at title="Article Title">LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair</at>. <pt title="Periodical Title">Nat Commun</pt> <yr title="Year">2015</yr>;<v title="Volume">6</v>:<pages title="Pages">8325</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/ncomms9325">https://doi.org/10.1038/ncomms9325</url> </jcit></bib><bib type="arabic" id="bib27" sno="27" suffix="."><jcit><au><s title="Surname">Herbert</s><f title="First name">K</f></au>, <au><s title="Surname">Binet</s><f title="First name">R</f></au>, <au><s title="Surname">Lambert</s><f title="First name">JP</f></au> <etal title="etal">et al.</etal> <at title="Article Title">BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma</at>. <pt title="Periodical Title">Genes Dev.</pt> <yr title="Year">2019</yr>;<v title="Volume">33</v>:<pages title="Pages">310–32</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gad.314633.118">https://doi.org/10.1101/gad.314633.118</url> </jcit></bib><bib type="arabic" id="bib28" sno="28" suffix="."><jcit><au><s title="Surname">Singh</s><f title="First name">JK</f></au>, <au><s title="Surname">Smith</s><f title="First name">R</f></au>, <au><s title="Surname">Rother</s><f title="First name">MB</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Zinc finger protein ZNF384 is an adaptor of ku to DNA during classical non-homologous end-joining</at>. <pt title="Periodical Title">Nat Commun</pt> <yr title="Year">2021</yr>;<v title="Volume">12</v>:<pages title="Pages">6560</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41467-021-26691-0">https://doi.org/10.1038/s41467-021-26691-0</url> </jcit></bib><bib type="arabic" id="bib29" sno="29" suffix="."><jcit><au><s title="Surname">Tang</s><f title="First name">M</f></au>, <au><s title="Surname">Chen</s><f title="First name">G</f></au>, <au><s title="Surname">Tu</s><f title="First name">B</f></au> <etal title="etal">et al.</etal> <at title="Article Title">SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity</at>. <pt title="Periodical Title">Sci. Adv.</pt> <yr title="Year">2023</yr>;<v title="Volume">9</v>:<pages title="Pages">eade6624</pages>. <url title="URL" type="uri" href="https://doi.org/10.1126/sciadv.ade6624">https://doi.org/10.1126/sciadv.ade6624</url> </jcit></bib><bib type="arabic" id="bib30" sno="30" suffix="."><jcit><au><s title="Surname">Martin</s><f title="First name">JF</f></au>, <au><s title="Surname">Bradley</s><f title="First name">A</f></au>, <au><s title="Surname">Olson</s><f title="First name">EN</f></au>. <at title="Article Title">The paired-like homeo box gene MHox is required for early events of skeletogenesis in multiple lineages</at>. <pt title="Periodical Title">Genes Dev.</pt> <yr title="Year">1995</yr>;<v title="Volume">9</v>:<pages title="Pages">1237–49</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gad.9.10.1237">https://doi.org/10.1101/gad.9.10.1237</url> </jcit></bib><bib type="arabic" id="bib31" sno="31" suffix="."><jcit><au><s title="Surname">Takano</s><f title="First name">S</f></au>, <au><s title="Surname">Reichert</s><f title="First name">M</f></au>, <au><s title="Surname">Bakir</s><f title="First name">B</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization</at>. <pt title="Periodical Title">Genes Dev.</pt> <yr title="Year">2016</yr>;<v title="Volume">30</v>:<pages title="Pages">233–47</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gad.263327.115">https://doi.org/10.1101/gad.263327.115</url> </jcit></bib><bib type="arabic" id="bib32" sno="32" suffix="."><jcit><au><s title="Surname">Lee</s><f title="First name">KW</f></au>, <au><s title="Surname">Yeo</s><f title="First name">SY</f></au>, <au><s title="Surname">Gong</s><f title="First name">JR</f></au> <etal title="etal">et al.</etal> <at title="Article Title">PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression</at>. <pt title="Periodical Title">Nat Commun</pt> <yr title="Year">2022</yr>;<v title="Volume">13</v>:<pages title="Pages">2793</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41467-022-30484-4">https://doi.org/10.1038/s41467-022-30484-4</url> </jcit></bib><bib type="arabic" id="bib33" sno="33" suffix="."><jcit><au><s title="Surname">Liu</s><f title="First name">H</f></au>, <au><s title="Surname">Li</s><f title="First name">P</f></au>, <au><s title="Surname">Zhang</s><f title="First name">S</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Prrx1 marks stem cells for bone, white adipose tissue and dermis in adult mice</at>. <pt title="Periodical Title">Nat Genet</pt> <yr title="Year">2022</yr>;<v title="Volume">54</v>:<pages title="Pages">1946–58</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41588-022-01227-4">https://doi.org/10.1038/s41588-022-01227-4</url> </jcit></bib><bib type="arabic" id="bib34" sno="34" suffix="."><jcit><au><s title="Surname">Marchand</s><f title="First name">B</f></au>, <au><s title="Surname">Pitarresi</s><f title="First name">JR</f></au>, <au><s title="Surname">Reichert</s><f title="First name">M</f></au> <etal title="etal">et al.</etal> <at title="Article Title">PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells</at>. <pt title="Periodical Title">Oncogene</pt> <yr title="Year">2019</yr>;<v title="Volume">38</v>:<pages title="Pages">4325–39</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41388-019-0725-6">https://doi.org/10.1038/s41388-019-0725-6</url> </jcit></bib><bib type="arabic" id="bib35" sno="35" suffix="."><jcit><au><s title="Surname">Fernandez-Martinez</s><f title="First name">J</f></au>, <au><s title="Surname">LaCava</s><f title="First name">J</f></au>, <au><s title="Surname">Rout</s><f title="First name">MP</f></au>. <at title="Article Title">Density gradient ultracentrifugation to isolate endogenous protein complexes after affinity capture</at>. <pt title="Periodical Title">Cold Spring Harb Protoc</pt> <yr title="Year">2016</yr>;<v title="Volume">2016</v>. <url title="URL" type="uri" href="https://doi.org/10.1101/pdb.prot087957">https://doi.org/10.1101/pdb.prot087957</url><query><button type="button" title="AU: Pages is missing in this reference &amp;lsqb;35&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="23" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">23</span></button></query></jcit></bib><bib type="arabic" id="bib36" sno="36" suffix="."><jcit><au><s title="Surname">Tang</s><f title="First name">S</f></au>, <au><s title="Surname">Bai</s><f title="First name">C</f></au>, <au><s title="Surname">Yang</s><f title="First name">P</f></au> <etal title="etal">et al.</etal> <at title="Article Title">14-3-3epsilon boosts bleomycin-induced DNA damage response by inhibiting the drug-resistant activity of MVP</at>. <pt title="Periodical Title">J. Proteome Res.</pt> <yr title="Year">2013</yr>;<v title="Volume">12</v>:<pages title="Pages">2511–24</pages>. <url title="URL" type="uri" href="https://doi.org/10.1021/pr301085c">https://doi.org/10.1021/pr301085c</url> </jcit></bib><bib type="arabic" id="bib37" sno="37" suffix="."><jcit><au><s title="Surname">Chen</s><f title="First name">Y</f></au>, <au><s title="Surname">Jiang</s><f title="First name">T</f></au>, <au><s title="Surname">Zhang</s><f title="First name">H</f></au> <etal title="etal">et al.</etal> <at title="Article Title">LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy</at>. <pt title="Periodical Title">Nat Cell Biol</pt> <yr title="Year">2020</yr>;<v title="Volume">22</v>:<pages title="Pages">1276–85</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41556-020-00586-6">https://doi.org/10.1038/s41556-020-00586-6</url> </jcit></bib><bib type="arabic" id="bib38" sno="38" suffix="."><jcit><au><s title="Surname">Endesfelder</s><f title="First name">D</f></au>, <au><s title="Surname">Burrell</s><f title="First name">R</f></au>, <au><s title="Surname">Kanu</s><f title="First name">N</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer</at>. <pt title="Periodical Title">Cancer Res</pt> <yr title="Year">2014</yr>;<v title="Volume">74</v>:<pages title="Pages">4853–63</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/0008-5472.CAN-13-2664">https://doi.org/10.1158/0008-5472.CAN-13-2664</url> </jcit></bib><bib type="arabic" id="bib39" sno="39" suffix="."><jcit><au><s title="Surname">Zhao</s><f title="First name">F</f></au>, <au><s title="Surname">Kim</s><f title="First name">W</f></au>, <au><s title="Surname">Gao</s><f title="First name">H</f></au> <etal title="etal">et al.</etal> <at title="Article Title">ASTE1 promotes shieldin-complex-mediated DNA repair by attenuating end resection</at>. <pt title="Periodical Title">Nat Cell Biol</pt> <yr title="Year">2021</yr>;<v title="Volume">23</v>:<pages title="Pages">894–904</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41556-021-00723-9">https://doi.org/10.1038/s41556-021-00723-9</url> </jcit></bib><bib type="arabic" id="bib40" sno="40" suffix="."><jcit><au><s title="Surname">Sztupinszki</s><f title="First name">Z</f></au>, <au><s title="Surname">Diossy</s><f title="First name">M</f></au>, <au><s title="Surname">Krzystanek</s><f title="First name">M</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer</at>. <pt title="Periodical Title">Npj Breast Cancer</pt> <yr title="Year">2018</yr>;<v title="Volume">4</v>:<pages title="Pages">16</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41523-018-0066-6">https://doi.org/10.1038/s41523-018-0066-6</url> </jcit></bib><bib type="arabic" id="bib41" sno="41" suffix="."><jcit><au><s title="Surname">Chen</s><f title="First name">B</f></au>, <au><s title="Surname">Ge</s><f title="First name">T</f></au>, <au><s title="Surname">Jian</s><f title="First name">M</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Transmembrane nuclease NUMEN/ENDOD1 regulates DNA repair pathway choice at the nuclear periphery</at>. <pt title="Periodical Title">Nat Cell Biol</pt> <yr title="Year">2023</yr>;<v title="Volume">25</v>:<pages title="Pages">1004–16</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41556-023-01165-1">https://doi.org/10.1038/s41556-023-01165-1</url> </jcit></bib><bib type="arabic" id="bib42" sno="42" suffix="."><jcit><au><s title="Surname">Varadi</s><f title="First name">M</f></au>, <au><s title="Surname">Anyango</s><f title="First name">S</f></au>, <au><s title="Surname">Deshpande</s><f title="First name">M</f></au> <etal title="etal">et al.</etal> <at title="Article Title">AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">2022</yr>;<v title="Volume">50</v>:<pages title="Pages">D439–44</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkab1061">https://doi.org/10.1093/nar/gkab1061</url> </jcit></bib><bib type="arabic" id="bib43" sno="43" suffix="."><jcit><au><s title="Surname">Kozakov</s><f title="First name">D</f></au>, <au><s title="Surname">Hall</s><f title="First name">DR</f></au>, <au><s title="Surname">Xia</s><f title="First name">B</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The ClusPro web server for protein-protein docking</at>. <pt title="Periodical Title">Nat Protoc</pt> <yr title="Year">2017</yr>;<v title="Volume">12</v>:<pages title="Pages">255–78</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nprot.2016.169">https://doi.org/10.1038/nprot.2016.169</url> </jcit></bib><bib type="arabic" id="bib44" sno="44" suffix="."><jcit><au><s title="Surname">Meng</s><f title="First name">EC</f></au>, <au><s title="Surname">Goddard</s><f title="First name">TD</f></au>, <au><s title="Surname">Pettersen</s><f title="First name">EF</f></au> <etal title="etal">et al.</etal> <at title="Article Title">UCSF ChimeraX: tools for structure building and analysis</at>. <pt title="Periodical Title">Protein Sci</pt> <yr title="Year">2023</yr>;<v title="Volume">32</v>:<pages title="Pages">e4792</pages>. <url title="URL" type="uri" href="https://doi.org/10.1002/pro.4792">https://doi.org/10.1002/pro.4792</url> </jcit></bib><bib type="arabic" id="bib45" sno="45" suffix="."><jcit><au><s title="Surname">Sugiyama</s><f title="First name">M</f></au>, <au><s title="Surname">Hasegawa</s><f title="First name">H</f></au>, <au><s title="Surname">Ito</s><f title="First name">S</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Paired related homeobox 1 is associated with the invasive properties of glioblastoma cells</at>. <pt title="Periodical Title">Oncol Rep</pt> <yr title="Year">2015</yr>;<v title="Volume">33</v>:<pages title="Pages">1123–30</pages>. <url title="URL" type="uri" href="https://doi.org/10.3892/or.2014.3681">https://doi.org/10.3892/or.2014.3681</url> </jcit></bib><bib type="arabic" id="bib46" sno="46" suffix="."><jcit><au><s title="Surname">Li</s><f title="First name">Y</f></au>, <au><s title="Surname">Wang</s><f title="First name">W</f></au>, <au><s title="Surname">Wang</s><f title="First name">F</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells</at>. <pt title="Periodical Title">J Mol Cell Biol</pt> <yr title="Year">2017</yr>;<v title="Volume">9</v>:<pages title="Pages">302–14</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/jmcb/mjx017">https://doi.org/10.1093/jmcb/mjx017</url> </jcit></bib><bib type="arabic" id="bib47" sno="47" suffix="."><jcit><au><s title="Surname">Dynan</s><f title="First name">WS</f></au>, <au><s title="Surname">Yoo</s><f title="First name">S</f></au>. <at title="Article Title">Interaction of Ku protein and DNA-dependent protein kinase catalytic subunit with nucleic acids</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">1998</yr>;<v title="Volume">26</v>:<pages title="Pages">1551–9</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/26.7.1551">https://doi.org/10.1093/nar/26.7.1551</url> </jcit></bib><bib type="arabic" id="bib48" sno="48" suffix="."><jcit><au><s title="Surname">Deriano</s><f title="First name">L</f></au>, <au><s title="Surname">Roth</s><f title="First name">DB</f></au>. <at title="Article Title">Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage</at>. <pt title="Periodical Title">Annu. Rev. Genet.</pt> <yr title="Year">2013</yr>;<v title="Volume">47</v>:<pages title="Pages">433–55</pages>. <url title="URL" type="uri" href="https://doi.org/10.1146/annurev-genet-110711-155540">https://doi.org/10.1146/annurev-genet-110711-155540</url> </jcit></bib><bib type="arabic" id="bib49" sno="49" suffix="."><jcit><au><s title="Surname">Yang</s><f title="First name">G</f></au>, <au><s title="Surname">Liu</s><f title="First name">C</f></au>, <au><s title="Surname">Chen</s><f title="First name">SH</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Super-resolution imaging identifies PARP1 and the ku complex acting as DNA double-strand break sensors</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">2018</yr>;<v title="Volume">46</v>:<pages title="Pages">3446–57</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gky088">https://doi.org/10.1093/nar/gky088</url> </jcit></bib><bib type="arabic" id="bib50" sno="50" suffix="."><jcit><au><s title="Surname">Escribano-Diaz</s><f title="First name">C</f></au>, <au><s title="Surname">Orthwein</s><f title="First name">A</f></au>, <au><s title="Surname">Fradet-Turcotte</s><f title="First name">A</f></au> <etal title="etal">et al.</etal> <at title="Article Title">A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice</at>. <pt title="Periodical Title">Mol Cell</pt> <yr title="Year">2013</yr>;<v title="Volume">49</v>:<pages title="Pages">872–83</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.molcel.2013.01.001">https://doi.org/10.1016/j.molcel.2013.01.001</url> </jcit></bib><bib type="arabic" id="bib51" sno="51" suffix="."><jcit><au><s title="Surname">Shibata</s><f title="First name">A</f></au>, <au><s title="Surname">Jeggo</s><f title="First name">PA</f></au>. <at title="Article Title">ATM’s role in the repair of DNA double-strand breaks</at>. <pt title="Periodical Title">Genes</pt> <yr title="Year">2021</yr>;<v title="Volume">12</v>. <url title="URL" type="uri" href="https://doi.org/10.3390/genes12091370">https://doi.org/10.3390/genes12091370</url> <query><button type="button" title="AU: Pages is missing in this reference &amp;lsqb;51&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="24" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">24</span></button></query></jcit></bib><bib type="arabic" id="bib52" sno="52" suffix="."><jcit><au><s title="Surname">Uematsu</s><f title="First name">N</f></au>, <au><s title="Surname">Weterings</s><f title="First name">E</f></au>, <au><s title="Surname">Yano</s><f title="First name">K</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks</at>. <pt title="Periodical Title">J Cell Biol</pt> <yr title="Year">2007</yr>;<v title="Volume">177</v>:<pages title="Pages">219–29</pages>. <url title="URL" type="uri" href="https://doi.org/10.1083/jcb.200608077">https://doi.org/10.1083/jcb.200608077</url> </jcit></bib><bib type="arabic" id="bib53" sno="53" suffix="."><jcit><au><s title="Surname">Jiang</s><f title="First name">W</f></au>, <au><s title="Surname">Crowe</s><f title="First name">JL</f></au>, <au><s title="Surname">Liu</s><f title="First name">X</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining</at>. <pt title="Periodical Title">Mol Cell</pt> <yr title="Year">2015</yr>;<v title="Volume">58</v>:<pages title="Pages">172–85</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.molcel.2015.02.024">https://doi.org/10.1016/j.molcel.2015.02.024</url> </jcit></bib><bib type="arabic" id="bib54" sno="54" suffix="."><jcit><au><s title="Surname">Bennardo</s><f title="First name">N</f></au>, <au><s title="Surname">Cheng</s><f title="First name">A</f></au>, <au><s title="Surname">Huang</s><f title="First name">N</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair</at>. <pt title="Periodical Title">PLoS Genet</pt> <yr title="Year">2008</yr>;<v title="Volume">4</v>:<pages title="Pages">e1000110</pages>. <url title="URL" type="uri" href="https://doi.org/10.1371/journal.pgen.1000110">https://doi.org/10.1371/journal.pgen.1000110</url> </jcit></bib><bib type="arabic" id="bib55" sno="55" suffix="."><jcit><au><s title="Surname">Mackenzie</s><f title="First name">KJ</f></au>, <au><s title="Surname">Carroll</s><f title="First name">P</f></au>, <au><s title="Surname">Martin</s><f title="First name">CA</f></au> <etal title="etal">et al.</etal> <at title="Article Title">cGAS surveillance of micronuclei links genome instability to innate immunity</at>. <pt title="Periodical Title">Nature</pt> <yr title="Year">2017</yr>;<v title="Volume">548</v>:<pages title="Pages">461–5</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nature23449">https://doi.org/10.1038/nature23449</url> </jcit></bib><bib type="arabic" id="bib56" sno="56" suffix="."><jcit><au><s title="Surname">Guan</s><f title="First name">J</f></au>, <au><s title="Surname">Lu</s><f title="First name">C</f></au>, <au><s title="Surname">Jin</s><f title="First name">Q</f></au> <etal title="etal">et al.</etal> <at title="Article Title">MLH1 Deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway</at>. <pt title="Periodical Title">Cancer Cell</pt> <yr title="Year">2021</yr>;<v title="Volume">39</v>:<pages title="Pages">109–121.e5e105</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.ccell.2020.11.004">https://doi.org/10.1016/j.ccell.2020.11.004</url> </jcit></bib><bib type="arabic" id="bib57" sno="57" suffix="."><jcit><au><s title="Surname">Zhang</s><f title="First name">ZD</f></au>, <au><s title="Surname">Zhong</s><f title="First name">B</f></au>. <at title="Article Title">Regulation and function of the cGAS-MITA/STING axis in health and disease</at>. <pt title="Periodical Title">Cell Insight</pt> <yr title="Year">2022</yr>;<v title="Volume">1</v>:<pages title="Pages">100001</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.cellin.2021.100001">https://doi.org/10.1016/j.cellin.2021.100001</url> </jcit></bib><bib type="arabic" id="bib58" sno="58" suffix="."><jcit><collab title="Collaborator" exinfo="author">Cancer Genome Atlas Research, N</collab>. <at title="Article Title">Comprehensive molecular characterization of gastric adenocarcinoma</at>. <pt title="Periodical Title">Nature</pt> <yr title="Year">2014</yr>;<v title="Volume">513</v>:<pages title="Pages">202–9</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nature13480">https://doi.org/10.1038/nature13480</url> </jcit></bib><bib type="arabic" id="bib59" sno="59" suffix="."><jcit><au><s title="Surname">Oh</s><f title="First name">SC</f></au>, <au><s title="Surname">Sohn</s><f title="First name">BH</f></au>, <au><s title="Surname">Cheong</s><f title="First name">JH</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype</at>. <pt title="Periodical Title">Nat Commun</pt> <yr title="Year">2018</yr>;<v title="Volume">9</v>:<pages title="Pages">1777</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41467-018-04179-8">https://doi.org/10.1038/s41467-018-04179-8</url> </jcit></bib><bib type="arabic" id="bib60" sno="60" suffix="."><jcit><au><s title="Surname">Jeong</s><f title="First name">YS</f></au>, <au><s title="Surname">Eun</s><f title="First name">YG</f></au>, <au><s title="Surname">Lee</s><f title="First name">SH</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Clinically conserved genomic subtypes of gastric adenocarcinoma</at>. <pt title="Periodical Title">Mol Cancer</pt> <yr title="Year">2023</yr>;<v title="Volume">22</v>:<pages title="Pages">147</pages>. <url title="URL" type="uri" href="https://doi.org/10.1186/s12943-023-01796-w">https://doi.org/10.1186/s12943-023-01796-w</url> </jcit></bib><bib type="arabic" id="bib61" sno="61" suffix="."><jcit><au><s title="Surname">Hnizda</s><f title="First name">A</f></au>, <au><s title="Surname">Tesina</s><f title="First name">P</f></au>, <au><s title="Surname">Nguyen</s><f title="First name">TB</f></au> <etal title="etal">et al.</etal> <at title="Article Title">SAP domain forms a flexible part of DNA aperture in Ku70/80</at>. <pt title="Periodical Title">FEBS J</pt> <yr title="Year">2021</yr>;<v title="Volume">288</v>:<pages title="Pages">4382–93</pages>. <url title="URL" type="uri" href="https://doi.org/10.1111/febs.15732">https://doi.org/10.1111/febs.15732</url> </jcit></bib><bib type="arabic" id="bib62" sno="62" suffix="."><jcit><au><s title="Surname">Wang</s><f title="First name">Y</f></au>, <au><s title="Surname">Czap</s><f title="First name">MS</f></au>, <au><s title="Surname">Kim</s><f title="First name">H</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The mammalian KU70 C-terminus SAP domain is required to repair exogenous DNA damage</at>. <pt title="Periodical Title">Biorxiv</pt> <yr title="Year">2024</yr><query><button type="button" title="AU: Volume and Pages are missing in this reference &amp;lsqb;65&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="25" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">25</span></button></query></jcit></bib><bib type="arabic" id="bib63" sno="63" suffix="."><othcit exinfo="journal"><au><s title="Surname">Zhu</s><f title="First name">Y</f></au>, <au><s title="Surname">Lee</s><f title="First name">BJ</f></au>, <au><s title="Surname">Fujii</s><f title="First name">S</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The KU70-SAP domain has an overlapping function with DNA-PKcs in limiting the lateral movement of KU along DNA</at>. <pt title="Periodical Title">Biorxiv</pt> <yr title="Year">2024</yr>;<misc1 title="Misc Text">2024.2008.2026.609806</misc1>.<query><button type="button" title="AU: Volume and Pages are missing in this reference &amp;lsqb;66&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="26" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">26</span></button></query></othcit></bib><bib type="arabic" id="bib64" sno="64" suffix="."><jcit><au><s title="Surname">Liu</s><f title="First name">W</f></au>, <au><s title="Surname">Miao</s><f title="First name">C</f></au>, <au><s title="Surname">Zhang</s><f title="First name">S</f></au> <etal title="etal">et al.</etal> <at title="Article Title">VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance</at>. <pt title="Periodical Title">Sig Transduct Target Ther</pt> <yr title="Year">2021</yr>;<v title="Volume">6</v>:<pages title="Pages">322</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41392-021-00735-9">https://doi.org/10.1038/s41392-021-00735-9</url></jcit></bib><bib type="arabic" id="bib65" sno="65" suffix="."><othcit exinfo="journal"><au><s title="Surname">Jin</s><f title="First name">H</f></au>, <au><s title="Surname">Lee</s><f title="First name">B</f></au>, <au><s title="Surname">Luo</s><f title="First name">Y</f></au> <etal title="etal">et al.</etal> <at title="Article Title">FOXL2 directs DNA double-strand break repair pathways by differentially interacting with Ku</at>. <pt title="Periodical Title">Nat Commun</pt> <yr title="Year">2020</yr>;<v title="Volume">11</v>, <yr title="Year">2010</yr><query><button type="button" title="AU: Pages is missing in this reference &amp;lsqb;62&amp;rsqb;. Please provide, if available." contenteditable="false" query-type="open" roleid="12" conversation-uid="27" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">27</span></button></query></othcit></bib><bib type="arabic" id="bib66" sno="66" suffix="."><jcit><au><s title="Surname">Schild-Poulter</s><f title="First name">C</f></au>, <au><s title="Surname">Pope</s><f title="First name">L</f></au>, <au><s title="Surname">Giffin</s><f title="First name">W</f></au> <etal title="etal">et al.</etal> <at title="Article Title">The binding of Ku antigen to homeodomain proteins promotes their phosphorylation by DNA-dependent protein kinase</at>. <pt title="Periodical Title">J Biol Chem</pt> <yr title="Year">2001</yr>;<v title="Volume">276</v>:<pages title="Pages">16848–56</pages>. <url title="URL" type="uri" href="https://doi.org/10.1074/jbc.M100768200">https://doi.org/10.1074/jbc.M100768200</url> </jcit></bib><bib type="arabic" id="bib67" sno="67" suffix="."><jcit><au><s title="Surname">Rubin</s><f title="First name">E</f></au>, <au><s title="Surname">Wu</s><f title="First name">X</f></au>, <au><s title="Surname">Zhu</s><f title="First name">T</f></au> <etal title="etal">et al.</etal> <at title="Article Title">A role for the HOXB7 homeodomain protein in DNA repair</at>. <pt title="Periodical Title">Cancer Res</pt> <yr title="Year">2007</yr>;<v title="Volume">67</v>:<pages title="Pages">1527–35</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/0008-5472.CAN-06-4283">https://doi.org/10.1158/0008-5472.CAN-06-4283</url> </jcit></bib><bib type="arabic" id="bib68" sno="68" suffix="."><jcit><au><s title="Surname">Renouf</s><f title="First name">B</f></au>, <au><s title="Surname">Soret</s><f title="First name">C</f></au>, <au><s title="Surname">Saandi</s><f title="First name">T</f></au> <etal title="etal">et al.</etal> <at title="Article Title">Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">2012</yr>;<v title="Volume">40</v>:<pages title="Pages">3456–69</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkr1242">https://doi.org/10.1093/nar/gkr1242</url> </jcit></bib><bib type="arabic" id="bib69" sno="69" suffix="."><jcit><au><s title="Surname">Ma</s><f title="First name">J</f></au>, <au><s title="Surname">Chen</s><f title="First name">T</f></au>, <au><s title="Surname">Wu</s><f title="First name">S</f></au> <etal title="etal">et al.</etal> <at title="Article Title">iProX: an integrated proteome resource</at>. <pt title="Periodical Title">Nucleic Acids Res</pt> <yr title="Year">2019</yr>;<v title="Volume">47</v>:<pages title="Pages">D1211–7</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gky869">https://doi.org/10.1093/nar/gky869</url> </jcit></bib><bib type="arabic" id="bib70" sno="70" suffix="."><jcit><au><s title="Surname">Zhou</s><f title="First name">C</f></au>, <au><s title="Surname">Li</s><f title="First name">S</f></au>, <au><s title="Surname">Bin</s><f title="First name">K</f></au> <etal title="etal">et al.</etal> <at title="Article Title">ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer</at>. <pt title="Periodical Title">Cancer Lett</pt> <yr title="Year">2022</yr>;<v title="Volume">547</v>:<pages title="Pages">215855</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.canlet.2022.215855">https://doi.org/10.1016/j.canlet.2022.215855</url> <query><button type="button" title="AU: Please note that the reference &amp;lsqb;63.&amp;rsqb; is not mentioned (cited) in the text. Add it to the text or delete it from the reference list by making changes directly in the text or references." contenteditable="false" query-type="open" roleid="12" conversation-uid="28" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">28</span></button></query></jcit></bib></ref></bm></doc>